STRYKER CORP, 10-K filed on 2/11/2022
Annual Report
v3.22.0.1
COVER PAGE - USD ($)
 12 Months Ended
Dec. 31, 2021
Jan. 31, 2022
Jun. 30, 2021
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-13149    
Entity Registrant Name STRYKER CORP    
Entity Incorporation, State or Country Code MI    
Entity Tax Identification Number 38-1239739    
Entity Address, Address Line One 2825 Airview Boulevard,    
Entity Address, City or Town Kalamazoo,    
Entity Address, State or Province MI    
Entity Address, Postal Zip Code 49002    
City Area Code (269)    
Local Phone Number 385-2600    
Title of 12(g) Security None    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Emerging Growth Company false    
Entity Small Business false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 91,942,474,363
Entity Common Stock, Shares Outstanding   377,544,686  
Documents Incorporated by Reference Portions of the proxy statement to be filed with the U.S. Securities and Exchange Commission relating to the 2022 Annual Meeting of Shareholders (the 2022 proxy statement) are incorporated by reference into Part III.    
Amendment Flag false    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000310764    
Common Stock, $.10 Par Value      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $.10 Par Value    
Trading Symbol SYK    
Security Exchange Name NYSE    
1.125% Notes due 2023      
Entity Information [Line Items]      
Title of 12(b) Security 1.125% Notes due 2023    
Trading Symbol SYK23    
Security Exchange Name NYSE    
0.250% Notes due 2024      
Entity Information [Line Items]      
Title of 12(b) Security 0.250% Notes due 2024    
Trading Symbol SYK24A    
Security Exchange Name NYSE    
2.125% Notes due 2027      
Entity Information [Line Items]      
Title of 12(b) Security 2.125% Notes due 2027    
Trading Symbol SYK27    
Security Exchange Name NYSE    
0.750% Notes due 2029      
Entity Information [Line Items]      
Title of 12(b) Security 0.750% Notes due 2029    
Trading Symbol SYK29    
Security Exchange Name NYSE    
2.625% Notes due 2030      
Entity Information [Line Items]      
Title of 12(b) Security 2.625% Notes due 2030    
Trading Symbol SYK30    
Security Exchange Name NYSE    
1.000% Notes due 2031      
Entity Information [Line Items]      
Title of 12(b) Security 1.000% Notes due 2031    
Trading Symbol SYK31    
Security Exchange Name NYSE    
v3.22.0.1
Audit Information
 12 Months Ended
Dec. 31, 2021
Auditor Information [Abstract]  
Auditor Firm ID 42
Auditor Name ERNST & YOUNG LLP
Auditor Location Grand Rapids, Michigan
v3.22.0.1
Consolidated Statements Of Earnings - USD ($)
$ in Thousands, shares in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Net sales $ 17,108,000 $ 14,351,000 $ 14,884,000
Cost of sales 6,140,000 5,294,000 5,188,000
Gross profit 10,968,000 9,057,000 9,696,000
Research, development and engineering expenses 1,235,000 984,000 971,000
Selling, general and administrative expenses 6,427,000 5,361,000 5,356,000
Recall charges 103,000 17,000 192,000
Amortization of intangible assets 619,000 472,000 464,000
Total operating expenses 8,384,000 6,834,000 6,983,000
Operating income 2,584,000 2,223,000 2,713,000
Other income (expense), net (303,000) (269,000) (151,000)
Earnings before income taxes 2,281,000 1,954,000 2,562,000
Income taxes 287,000 355,000 479,000
Net earnings $ 1,994,000 $ 1,599,000 $ 2,083,000
Net earnings per share of common stock:      
Basic net earnings per share of common stock (in dollars per share) $ 5.29 $ 4.26 $ 5.57
Diluted net earnings per share of common stock (in dollars per share) $ 5.21 $ 4.20 $ 5.48
Weighted-average shares outstanding (in millions):      
Basic (in shares) 377.0 375.5 374.0
Effect of dilutive employee stock compensation (in shares) 5.3 4.8 5.9
Diluted (in shares) 382.3 380.3 379.9
v3.22.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]      
Net earnings $ 1,994 $ 1,599 $ 2,083
Other comprehensive income (loss), net of tax      
Marketable securities 3 0 1
Pension plans 104 (80) (42)
Unrealized gains (losses) on designated hedges 50 (57) (3)
Financial statement translation 469 (414) 69
Total other comprehensive income (loss), net of tax 626 (551) 25
Comprehensive income $ 2,620 $ 1,048 $ 2,108
v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 2,944 $ 2,943
Marketable securities 75 81
Accounts receivable, less allowance of $167 ($131 in 2020) 3,022 2,701
Inventories:    
Materials and supplies 691 678
Work in process 264 251
Finished goods 2,359 2,565
Total inventories 3,314 3,494
Prepaid expenses and other current assets 662 488
Total current assets 10,017 9,707
Property, plant and equipment:    
Land, buildings and improvements 1,656 1,546
Machinery and equipment 3,842 3,636
Total property, plant and equipment 5,498 5,182
Less allowance for depreciation 2,665 2,430
Property, plant and equipment, net 2,833 2,752
Goodwill 12,918 12,778
Other intangibles, net 4,840 5,554
Noncurrent deferred income tax assets 1,760 1,530
Other noncurrent assets 2,263 2,009
Total assets 34,631 34,330
Current liabilities    
Accounts payable 1,129 810
Accrued compensation 1,092 925
Income taxes 192 207
Dividend payable 263 237
Accrued product liabilities 401 515
Accrued expenses and other liabilities 1,465 1,586
Current maturities of debt 7 761
Total current liabilities 4,549 5,041
Long-term debt, excluding current maturities 12,472 13,230
Income taxes 913 990
Other noncurrent liabilities 1,820 1,985
Total liabilities 19,754 21,246
Shareholders' equity    
Common stock, $0.10 par value 38 38
Additional paid-in capital 1,890 1,741
Retained earnings 13,480 12,462
Accumulated other comprehensive loss (531) (1,157)
Total shareholders' equity 14,877 13,084
Total liabilities & shareholders' equity $ 34,631 $ 34,330
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
v3.22.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 167 $ 131
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
v3.22.0.1
Consolidated Statements Of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2018   $ 37 $ 1,559 $ 10,765 $ (631)
Beginning balance, shares at Dec. 31, 2018   374.4      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock compensation and benefit plans   $ 0 (50)    
Issuance of common stock under stock compensation and benefit plans, shares   2.0      
Repurchase of common stock   $ 0 (8) (299)  
Repurchase of common stock, shares   (1.9)      
Share-based compensation     127    
Net earnings $ 2,083     2,083  
Cash dividends declared       (801)  
Other comprehensive income (loss) 25       25
Ending balance, shares at Dec. 31, 2019   374.5      
Ending balance at Dec. 31, 2019 12,807 $ 37 1,628 11,748 (606)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock compensation and benefit plans   $ 1 (29)    
Issuance of common stock under stock compensation and benefit plans, shares   1.6      
Repurchase of common stock   $ 0 0 0  
Repurchase of common stock, shares   0.0      
Share-based compensation     142    
Net earnings 1,599     1,599  
Cash dividends declared       (885)  
Other comprehensive income (loss) (551)       (551)
Ending balance, shares at Dec. 31, 2020   376.1      
Ending balance at Dec. 31, 2020 13,084 $ 38 1,741 12,462 (1,157)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock compensation and benefit plans   $ 0 (22)    
Issuance of common stock under stock compensation and benefit plans, shares   1.4      
Repurchase of common stock   $ 0 0 0  
Repurchase of common stock, shares   0.0      
Share-based compensation     171    
Net earnings 1,994     1,994  
Cash dividends declared       (976)  
Other comprehensive income (loss) 626        
Ending balance, shares at Dec. 31, 2021   377.5      
Ending balance at Dec. 31, 2021 $ 14,877 $ 38 $ 1,890 $ 13,480 $ (531)
v3.22.0.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities      
Net earnings $ 1,994 $ 1,599 $ 2,083
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation 371 340 314
Amortization of intangible assets 619 472 464
Asset impairments 264 215 16
Share-based compensation 171 142 127
Recall charges 103 17 192
Sale of inventory stepped up to fair value at acquisition 266 48 67
Deferred income tax (benefit) expense (237) 48 126
Changes in operating assets and liabilities:      
Accounts receivable (377) 354 (563)
Inventories (189) 27 (400)
Accounts payable 329 100 63
Accrued expenses and other liabilities 315 (54) 113
Recall-related payments (221) (17) (177)
Income taxes (98) (16) (105)
Other, net (47) 2 (129)
Net cash provided by operating activities 3,263 3,277 2,191
Investing activities      
Acquisitions, net of cash acquired (339) (4,222) (802)
Purchases of marketable securities (49) (54) (74)
Proceeds from sales of marketable securities 55 61 69
Purchases of property, plant and equipment (525) (487) (649)
Other investing, net (1) 1 1
Net cash used in investing activities (859) (4,701) (1,455)
Financing activities      
Proceeds and payments on short-term borrowings, net (7) (6) (7)
Proceeds from issuance of long-term debt 5 3,292 2,642
Payments on long-term debt (1,151) (2,297) (1,342)
Payments of dividends (950) (863) (778)
Repurchases of common stock 0 0 (307)
Cash paid for taxes from withheld shares (114) (110) (136)
Other financing, net (148) (27) (69)
Net cash provided by (used in) financing activities (2,365) (11) 3
Effect of exchange rate changes on cash and cash equivalents (38) 41 (18)
Change in cash and cash equivalents 1 (1,394) 721
Cash and cash equivalents at beginning of year 2,943 4,337 3,616
Cash and cash equivalents at end of year 2,944 2,943 4,337
Supplemental cash flow disclosure:      
Cash paid for income taxes, net of refunds 622 323 457
Cash paid for interest on debt $ 325 $ 304 $ 286
v3.22.0.1
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Significant Accounting Policies [Abstract]  
Significant Accounting Policies SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations: Stryker (the "Company," "we," "us," or "our") is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties.
Basis of Presentation and Consolidation: The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities and none that require consolidation. Prior years' segment results have been reclassified to conform with current year presentation in our Consolidated Financial Statements.
Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of net sales and expenses in the reporting period. Actual results could differ from those estimates.
Revenue Recognition: Sales are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. Our sales are recognized primarily when we transfer control to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time.
Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality.
A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales returns has been established based on contract terms with our customers and historical business practices and current trends. Shipping and handling costs charged to customers are included in net sales.
Cost of Sales: Cost of sales is primarily comprised of direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct
overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity.
Research, Development and Engineering Expenses: Research, development and engineering costs are charged to expense as incurred. Costs include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment.
Selling, General and Administrative Expenses: Selling, general and administrative expense is primarily comprised of selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items.
Currency Translation: Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States Dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in other income (expense), net.
Cash Equivalents: Highly liquid investments with remaining stated maturities of three months or less when purchased or other money market instruments that are redeemable upon demand are considered cash equivalents and recorded at cost.
Marketable Securities: Marketable securities consist of marketable debt securities, certificates of deposit and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities and are recognized in other noncurrent assets. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Investments in trading securities represent participant-directed investments of deferred employee compensation.
Accounts Receivable: Accounts receivable consists of trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience, current market conditions and expected credit losses. Accounts receivable are written off when all reasonable collection efforts are exhausted.
Inventories: Inventories are stated at the lower of cost or net realizable value, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to net realizable value.
Financial Instruments: Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2021 and 2020. Refer to Notes 3 and 10 for further details.
All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recognized as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recognized in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method.
We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI.
Derivatives: All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period.
Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. These nonfunctional currency exposures principally relate to forecasted intercompany sales and purchases of manufactured products and generally have maturities up to eighteen months. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in cost of goods sold in the Consolidated Statements of Earnings. Cash flows associated with these hedges are included in cash from operations in the same category as the cash flows from the items being hedged.
Forward currency exchange contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities, primarily intercompany payables and receivables. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the
measurement of the contracts at month-end spot rates as adjusted by current forward points.
From time to time, we designate derivative and non-derivative financial instruments as net investment hedges of our investments in certain international subsidiaries. For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is recognized in OCI and reported as a component of AOCI. We have elected to use the spot method to assess effectiveness for our derivatives designated as net investment hedges. Accordingly, the change in fair value attributable to changes in the spot rate is recorded in AOCI. We exclude the spot-forward difference from the assessment of hedge effectiveness and amortize this amount separately on a straight-line basis over the term of the forward contracts. This amortization is recognized in other income (expense), net.
From time to time, we designate forward starting interest rate derivative instruments as cash flow hedges to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in interest expense in the Consolidated Statements of Earnings.
Interest rate derivative instruments designated as fair value hedges have been used in the past to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.
Property, Plant and Equipment: Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.
Goodwill and Other Intangible Assets: Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio.
The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below.
In some of our acquisitions, we acquire in-process research and development (IPRD) intangible assets. For acquisitions accounted for as business combinations IPRD is considered to
be an indefinite-lived intangible asset until the research is completed (then it becomes a determinable-lived intangible asset) or determined to have no future use (then it is impaired). For asset acquisitions IPRD is expensed immediately unless there is an alternative future use.
Goodwill, Intangibles and Long-Lived Asset Impairment Tests: We perform our annual impairment test for goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill and periodically corroborate that assessment with quantitative information. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value.
We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale are recorded at the lower of carrying amount or fair value less costs to sell.
Share-Based Compensation: Share-based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long-term incentive plans to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments.
We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals in that three-year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.
Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to
determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.
Income Taxes: Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities in the year. Other amounts result from adjustments related to acquisitions and foreign currency as appropriate.
We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.
New Accounting Pronouncements Not Yet Adopted
In October 2021 the Financial Accounting Standards Board issued Accounting Standards Update 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers. We are evaluating the impact this update will have on our Consolidated Financial Statements.
Accounting Pronouncements Recently Adopted
No new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our Consolidated Financial Statements.
v3.22.0.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2021
Revenue Recognition [Abstract]  
Revenue Recognition REVENUE RECOGNITION
We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.
Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In 2021 less than 10% of our sales were recognized as services transferred over time. Refer to Note 1 for further discussion on our revenue recognition policies.
Segment Net Sales
MedSurg and Neurotechnology:202120202019
Instruments$2,111 $1,863 $1,959 
Endoscopy2,141 1,763 1,983 
Medical2,607 2,524 2,264 
Neurovascular1,188 973 924 
Neuro Cranial1,214 972 1,059 
Other277 250 286 
$9,538 $8,345 $8,475 
Orthopaedics and Spine:
Knees$1,848 $1,567 $1,815 
Hips1,342 1,206 1,383 
Trauma and Extremities2,664 1,722 1,639 
Spine1,167 1,047 1,157 
Other549 464 415 
$7,570 $6,006 $6,409 
Total$17,108 $14,351 $14,884 
United States Net Sales
MedSurg and Neurotechnology:202120202019
Instruments$1,637 $1,471 $1,542 
Endoscopy1,670 1,408 1,577 
Medical2,007 1,910 1,787 
Neurovascular451 381 391 
Neuro Cranial988 801 890 
Other273 247 283 
$7,026 $6,218 $6,470 
Orthopaedics and Spine:
Knees$1,351 $1,170 $1,347 
Hips822 777 882 
Trauma and Extremities1,866 1,139 1,051 
Spine831 764 873 
Other425 387 334 
$5,295 $4,237 $4,487 
Total$12,321 $10,455 $10,957 
International Net Sales
MedSurg and Neurotechnology:202120202019
Instruments$474 $392 $417 
Endoscopy471 355 406 
Medical600 614 477 
Neurovascular737 592 533 
Neuro Cranial226 171 169 
Other4 3 3 
$2,512 $2,127 $2,005 
Orthopaedics and Spine:
Knees$497 $397 $468 
Hips520 429 501 
Trauma and Extremities798 583 588 
Spine336 283 284 
Other124 77 81 
$2,275 $1,769 $1,922 
Total$4,787 $3,896 $3,927 
MedSurg and Neurotechnology
MedSurg and Neurotechnology products include surgical equipment and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke (Neurovascular), a comprehensive line of products for traditional brain and open skull based surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral
augmentation products (Neuro Cranial) and other medical device products used in a variety of medical specialties. Substantially all MedSurg and Neurotechnology sales are recognized when a purchase order has been received and control has transferred. For certain Endoscopy, Instruments and Medical services, we may recognize sales over time as we satisfy performance obligations that may include an obligation to complete installation, provide training and perform ongoing services, generally performed within one year.
Orthopaedics and Spine
Orthopaedics and Spine products consist primarily of implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. Substantially all Orthopaedics sales are recognized when we have received a purchase order and appropriate notification the product has been used or implanted. Substantially all Spine sales are recognized when a purchase order has been received and control has transferred. For certain Orthopaedic products in the "other" category, we recognize sales at a point in time, as well as over time for performance obligations that may include an obligation to complete installation and provide training and ongoing services. Performance obligations are generally satisfied within one year.
Contract Assets and Liabilities
The nature of our products and services do not generally give rise to contract assets as we typically do not incur costs to fulfill a contract before a product or service is provided to a customer. Our costs to obtain contracts are typically in the form of sales commissions paid to employees or third-party agents. Certain sales commissions paid to employees prior to recognition of sales are recorded as contract assets. We expense sales commissions associated with obtaining a contract at the time of the sale or as incurred as the amortization period is generally less than one year. These costs have been presented within selling, general and administrative expenses. On December 31, 2021 contract assets recorded in our Consolidated Balance Sheets were not significant.
Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $529 and $416 on December 31, 2021 and December 31, 2020.
v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified in their entirety based on the lowest level of input and disclosed in one of the following three categories:
Level 1Quoted market prices in active markets for identical assets or liabilities.
Level 2Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3Unobservable inputs reflecting our assumptions or external inputs from active markets.
Use of observable market data, when available, is required in making fair value measurements. When inputs used fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. We
determine fair value for Level 1 instruments using exchange-traded prices for identical instruments. We determine fair value of Level 2 instruments using exchange-traded prices of similar instruments, where available, or utilizing other observable inputs that take into account our credit risk and that of our counterparties. Foreign currency exchange contracts and interest rate hedges are included in Level 2 and we use inputs other than quoted prices that are observable for the asset or liability. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis. Our Level 3 liabilities are comprised of contingent consideration arising from recently completed acquisitions. We determine fair value of these Level 3 liabilities using a discounted cash flow technique. Significant unobservable inputs were used in our assessment of fair value, including assumptions regarding future business results, discount rates, discount periods and probability assessments based on the likelihood of reaching various targets. We remeasure the fair value of our assets and liabilities each reporting period. We record the changes in fair value within selling, general and administrative expense and the changes in the time value of money within other income (expense), net.
Assets Measured at Fair Value
20212020
Cash and cash equivalents$2,944 $2,943 
Trading marketable securities193 171 
Level 1 - Assets$3,137 $3,114 
Available-for-sale marketable securities:
Corporate and asset-backed debt securities$48 $38 
Foreign government debt securities2 — 
United States agency debt securities5 5 
United States treasury debt securities19 36 
Certificates of deposit1 2 
Total available-for-sale marketable securities$75 $81 
Foreign currency exchange forward contracts212 20 
Level 2 - Assets$287 $101 
Total assets measured at fair value$3,424 $3,215 
Liabilities Measured at Fair Value
20212020
Deferred compensation arrangements$193 $171 
Level 1 - Liabilities$193 $171 
Foreign currency exchange forward contracts$17 $160 
Interest rate swap liability— 53 
Level 2 - Liabilities$17 $213 
Contingent consideration:
Beginning$393 $306 
Additions62 108 
Change in estimate (1)9 
Settlements(148)(30)
Ending$306 $393 
Level 3 - Liabilities$306 $393 
Total liabilities measured at fair value$516 $777 
Fair Value of Available for Sale Securities by Maturity
20212020
Due in one year or less$36 $42 
Due after one year through three years$39 $39 
On December 31, 2021 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income was $68, $102 and $155 in 2021, 2020 and 2019, which was recorded in other income (expense), net.
Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the
investments before recovery of their amortized cost basis, which may be maturity.
v3.22.0.1
Derivative Instruments
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments DERIVATIVE INSTRUMENTS
We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument.
Foreign Currency Hedges
2021Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$973 $2,266 $5,512 $8,751 
Maximum term in years4.9
Fair value:
Other current assets$15 $39 $92 $146 
Other noncurrent assets1 65 — 66 
Other current liabilities(7)— (10)(17)
Total fair value$9 $104 $82 $195 
2020
Gross notional amount$949 $1,828 $5,382 $8,159 
Maximum term in years4.9
Fair value:
Other current assets$9 $— $7 $16 
Other noncurrent assets— 4 — 4 
Other current liabilities(12)— (121)(133)
Other noncurrent liabilities(1)(26)— (27)
Total fair value$(4)$(22)$(114)$(140)
We had €2.0 billion and €1.5 billion at December 31, 2021 and 2020 in certain forward currency contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at December 31, 2021 and 2020 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.
On December 31, 2021 the total after-tax gain (loss) in AOCI related to designated net investment hedges was ($34).
Net Currency Exchange Rate Gains (Losses)
Derivative InstrumentRecorded in:202120202019
Cash FlowCost of sales$(12)$5 $2 
Net InvestmentOther income (expense), net35 28 14 
Non-DesignatedOther income (expense), net(10)(13)(7)
Total$13 $20 $9 
Pretax gains (losses) on derivatives designated as cash flow hedges of $9 and net investment hedges of $37 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of December 31, 2021. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge
instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment.
Interest Rate Hedges
In 2021 a loss of $11 was reclassified from AOCI to other income (expense), net in earnings relating to the termination of forward starting interest rate swaps with notional amounts of $750 designated as cash flow hedges as we now consider it probable that the original forecasted debt issuances will not occur. Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of December 31, 2021. The cash flow effect of interest rate hedges is recorded in cash flow from operations.
v3.22.0.1
Accumulated Other Comprehensive (Loss) Income (AOCI)
 12 Months Ended
Dec. 31, 2021
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]  
Accumulated Other Comprehensive (Loss) Income (AOCI) ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)
Marketable SecuritiesPension PlansHedgesFinancial Statement TranslationTotal
2019$(3)$(179)$47 $(471)$(606)
OCI— (117)(64)(459)(640)
Income taxes— 28 17 66 111 
Reclassifications to:
Cost of Sales— — (5)— (5)
Other (income) expense, net— 12 (6)(28)(22)
Income taxes— (3)1 7 5 
Net OCI— (80)(57)(414)(551)
2020$(3)$(259)$(10)$(885)$(1,157)
OCI4 123 46 551 724 
Income taxes— (32)(15)(54)(101)
Reclassifications to:
Cost of Sales— — 12 — 12 
Other (income) expense, net— 15 6 (35)(14)
Income taxes(1)(2)1 7 5 
Net OCI3 104 50 469 626 
2021$— $(155)$40 $(416)$(531)
v3.22.0.1
Acquisitions
 12 Months Ended
Dec. 31, 2021
Business Combinations [Abstract]  
Acquisitions ACQUISITIONS
We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $393 and $4,304 in 2021 and 2020.
In September 2021 we completed the acquisition of Gauss Surgical, Inc. (Gauss) for $120 in cash and up to $40 in future milestone payments. Gauss is a medical device company that has developed Triton, an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery. Gauss is part of our Instruments business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition is not deductible for tax purposes.
In November 2020 we completed the acquisition of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of $4.1 billion ($5.6 billion including convertible notes). Wright is a global medical device company focused on extremities and biologics. Wright is part of our Trauma and Extremities business within Orthopaedics and Spine. Goodwill attributable to the acquisition is not deductible for tax purposes.
In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576. These repayments are classified as financing activities.
In December 2020 we completed the acquisition of OrthoSensor, Inc. (OrthoSensor). OrthoSensor is a leader in the digital evolution of musculoskeletal care and sensor technology for total joint replacement. OrthoSensor is part of our Joint Replacement business within Orthopaedics and Spine. Goodwill attributable to the acquisition is not deductible for tax purposes.
Had the above acquisitions taken place as of the beginning of the comparable prior year, our consolidated financial results of operations in the aggregate would not have been materially different. Accordingly, we have not disclosed pro forma financial information.
Purchase price allocations for our significant acquisitions are:
Purchase Price Allocation of Acquired Net Assets
2020Wright
Tangible assets acquired:
Accounts receivable$127 
Deferred income tax assets491 
Inventory440 
Other assets343 
Debt(1,446)
Deferred income tax liabilities(503)
Product liabilities(218)
Other liabilities(296)
Intangible assets:
Customer and distributor relationships182 
Developed technology and patents1,506 
Trade name58 
Goodwill3,397 
Purchase price, net of cash acquired$4,081 
Weighted average life of intangible assets12
Purchase price allocations for 2021 acquisitions were based on preliminary valuations, primarily related to intangible assets, product liabilities and deferred income taxes. Our estimates and assumptions are subject to change within the measurement period. The purchase price allocations for Wright, OrthoSensor and other 2020 acquisitions were finalized in 2021 without material adjustments.
In January 2022 we announced a definitive merger agreement to acquire all of the issued and outstanding common shares of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of approximately $3.1 billion (including convertible notes). Pursuant to the agreement we commenced a tender offer to purchase all of the outstanding shares of common stock of Vocera for $79.25 per share in cash. The boards of directors of both Stryker and Vocera have unanimously approved the transaction. We expect the acquisition to close in the first quarter of 2022, subject to completion of the tender offer and other customary conditions. Vocera has emerged as a leading platform in the digital care coordination and communication category. Following closing, we plan to integrate Vocera into our Medical business within MedSurg and Neurotechnology.
v3.22.0.1
Contingencies and Commitments
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Commitments CONTINGENCIES AND COMMITMENTSWe are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to
reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.
Recall Matters
In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against.
In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. In December 2021, we reached a second agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreements, including the financial terms, are confidential.
With the acquisition of Wright as more fully described in Note 6, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright prior to its 2014 divestiture of the OrthoRecon business. We will continue to evaluate each claim and the possible loss we may incur.
We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. In 2021, we recorded charges of $103 and made payments of $221, primarily related to Rejuvenate and ABG II Modular-Neck hip stems. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.
Leases
We lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. We evaluate our contracts to identify leases, which is generally if there is an identified asset and we
have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. Certain of our lease agreements contain rent escalation clauses (including index-based escalations), rent holidays, capital improvement funding or other lease incentives. We recognize our minimum rental expense on a straight-line basis over the term of the lease beginning with the date of initial control of the asset. Right-of-use assets are recorded in Other noncurrent assets on our Consolidated Balance Sheets. Current and noncurrent lease liabilities are recorded in Accrued expenses and other liabilities and Other noncurrent liabilities, respectively.
We have made certain significant assumptions and judgments when recording leases. For all asset classes, we elected to not recognize a right-of-use asset and lease liability for short-term leases and not separate non-lease components from lease components to which they relate and have accounted for the combined lease and non-lease components as a single lease component. The determination of the discount rate used in a lease is our incremental borrowing rate which is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.
20212020
Right-of-use assets $419 $423 
Lease liabilities, current $112 $109 
Lease liabilities, noncurrent $310 $325 
Other information:
Weighted-average remaining lease term 5.4 years5.6 years
Weighted-average discount rate2.86 %2.57 %
Operating lease expense totaled $133, $130, and $133 in 2021, 2020 and 2019.
Future Obligations
We have purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. In addition, we lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. Refer to Note 10 for more information on the debt obligations.
20222023202420252026Thereafter
Debt repayments$7 $1,226 $1,564 $1,400 $1,000 $7,392 
Purchase obligations$1,889 $69 $54 $46 $49 $— 
Minimum lease payments$112 $86 $60 $38 $34 $72 
v3.22.0.1
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS
We completed our annual impairment tests of goodwill in 2021 and 2020 and concluded in each year that no impairments exist.

Changes in the Net Carrying Value of Goodwill by Segment
MedSurg and NeurotechnologyOrthopaedics and SpineTotal
2019$5,377 $3,692 $9,069 
Additions and adjustments1 3,558 3,559 
Foreign exchange81 69 150 
2020$5,459 $7,319 $12,778 
Additions and adjustments223 59 282 
Foreign exchange(13)(129)(142)
2021$5,669 $7,249 $12,918 
Summary of Other Intangible Assets
Weighted Average Amortization Period (Years)Gross
Carrying
Amount		Less
Accumulated
Amortization		Net
Carrying
Amount
Developed technologies
202113$5,326 $1,956 $3,370 
2020135,305 1,573 3,732 
Customer relationships
202115$2,324 $1,174 $1,150 
2020152,352 988 1,364 
Patents
202112$343 $286 $57 
202012346 278 68 
Trademarks
202116$415 $199 $216 
202017428 162 266 
In-process research and development
2021N/A$29 $— $29 
2020N/A97 — 97 
Other
20219$105 $87 $18 
20208128 101 27 
Total
202114$8,542 $3,702 $4,840 
2020148,656 3,102 5,554 
Estimated Amortization Expense
20222023202420252026
$581 $558 $528 $506 $447 
v3.22.0.1
Capital Stock
 12 Months Ended
Dec. 31, 2021
Capital Stock [Abstract]  
Capital Stock CAPITAL STOCK
The aggregate number of shares of all classes of stock which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10. No shares of preferred stock were outstanding on December 31, 2021.
We made no repurchases of shares in 2021. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price and other factors and are subject to regulatory considerations. Purchases are made from time-to-time in the open market, in privately negotiated transactions or otherwise. On December 31, 2021 the total dollar value of shares that could be purchased under our authorized repurchase program was $1,033.
Shares reserved for future compensation grants of our common stock were 25 million and 28 million on December 31, 2021 and 2020.
Stock Options
We measure the cost of employee stock options based on the grant-date fair value and recognize that cost using the straight-line method over the period in which a recipient is required to provide services in exchange for the options, typically the vesting period. The weighted-average fair value per share of options is estimated on the date of grant using the Black-Scholes option pricing model.
Option Value and Assumptions
202120202019
Weighted-average fair value per share$53.35 $39.34 $36.30 
Assumptions:
Risk-free interest rate0.8 %1.4 %2.6 %
Expected dividend yield1.2 %1.0 %1.1 %
Expected stock price volatility26.9 %18.9 %18.3 %
Expected option life (years)5.95.85.9
The risk-free interest rate for periods within the expected life of options granted is based on the United States Treasury yield
curve in effect at the time of grant. Expected stock price volatility is based on the historical volatility of our stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data.
2021 Stock Option Activity
Shares
(in millions)		Weighted
Average
Exercise Price		Weighted-Average
Remaining
Term (in years)		Aggregate
Intrinsic
 Value
Outstanding January 112.2 $131.72 
Granted1.8 235.35 
Exercised(1.6)96.41 
Canceled or forfeited(0.3)192.60 
Outstanding December 3112.1 $150.17 5.7$1,424.2 
Exercisable December 317.1 $113.56 4.2$1,086.3 
Options expected to vest4.6 $199.41 7.7$313.3 
The aggregate intrinsic value of options, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, exercised was $253, $258, and $294 in 2021, 2020 and 2019. Exercise prices for options outstanding ranged from $53.60 to $270.94 on December 31, 2021. On December 31, 2021 there was $101 of unrecognized compensation cost related to nonvested stock options granted under the long-term incentive plans; that cost is expected to be recognized over the weighted-average period of approximately 1.5 years.
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Activity
Shares
(in millions)		Weighted Average
Grant Date Fair Value
RSUsPSUsRSUsPSUs
Nonvested on January 10.8 0.2 $187.72 $185.46 
Granted0.4 0.1 230.61 233.95 
Vested(0.4)(0.1)179.15 153.67 
Canceled or forfeited(0.1)— 187.38 160.11 
Nonvested on December 310.7 0.2 $213.16 $210.73 
On December 31, 2021 there was $71 of unrecognized compensation cost related to nonvested RSUs. That cost is expected to be recognized as expense over the weighted-average period of approximately one year. The weighted-average grant date fair value per share of RSUs granted was $230.61 and $208.96 in 2021 and 2020. The fair value of RSUs and PSUs vested in 2021 was $63 and $5. On December 31, 2021 there was $18 of unrecognized compensation cost related to nonvested PSUs; the cost is expected to be recognized as expense over the weighted-average period of approximately one year.
Employee Stock Purchase Plans (ESPP)
Employees may participate in our ESPP provided they meet certain eligibility requirements. The purchase price for our common stock under the terms of the ESPP is defined as 95% of the closing stock price on the last trading day of a purchase period. We issued 183,964 and 209,837 shares under the ESPP in 2021 and 2020.
v3.22.0.1
Debt and Credit Facilities
 12 Months Ended
Dec. 31, 2021
Long-term Debt, Unclassified [Abstract]  
Debt And Credit Facilities DEBT AND CREDIT FACILITIESWe have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on December 31, 2021.
In October 2021 we entered into a new revolving credit agreement that replaces our previous agreement dated August 19, 2016. The primary changes were to increase the aggregate principal amount of the facility by $750 to $2,250, extend the maturity date to October 26, 2026, increase the leverage ratio to 3.75 and provide LIBOR replacement language.
In the first quarter of 2022, our Board of Directors approved an increase to the maximum amount of commercial paper that can be outstanding under our commercial paper program from $1,500 to $2,250, with maturities up to 397 days from the date of issuance. On December 31, 2021 there were no borrowings outstanding under our credit facility or commercial paper program.
Summary of Total Debt
Senior unsecured notes:
RateDue20212020
2.625%March 15, 2021$— $750 
1.125%November 30, 2023622 668 
0.600%December 1, 2023598 597 
3.375%May 15, 2024593 590 
0.250%December 3, 2024958 1,030 
1.150%June 15, 2025645 644 
3.375%November 1, 2025748 747 
3.500%March 15, 2026994 992 
2.125%November 30, 2027845 909 
3.650%March 7, 2028597 596 
0.750%March 1, 2029901 969 
1.950%June 15, 2030990 989 
2.625%November 30, 2030727 782 
1.000%December 3, 2031840 903 
4.100%April 1, 2043392 392 
4.375%May 15, 2044395 395 
4.625%March 15, 2046982 981 
2.900%June 15, 2050642 641 
Term loan— 400 
Other10 16 
Total debt$12,479 $13,991 
Less current maturities7 761 
Total long-term debt$12,472 $13,230 
Unamortized debt issuance costs$62 $71 
Borrowing capacity on existing facilities$2,162 $2,903 
Fair value of senior unsecured notes$13,391 $15,022 
The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy.
In March 2021 we repaid $750 of senior unsecured notes with a coupon of 2.625% that were due on March 15, 2021.
In June 2021 we repaid the $400 term loan that was due on November 10, 2023.
Interest expense, including required fees incurred on outstanding debt and credit facilities that were included in other income (expense), net, totaled $337, $315, and $287 in 2021, 2020 and 2019.
v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES Our effective tax rate was 12.6%, 18.2% and 18.7% for 2021, 2020 and 2019. The effective income tax rate for 2021 reflects the continued lower effective income tax rates as a result of our European operations, certain discrete tax benefits, the tax effect related to the transfer of intellectual property between tax jurisdictions and the tax effect of future remittances of the undistributed earnings of foreign subsidiaries. The effective
income tax rate for 2020 and 2019 reflects the tax effect related to the transfer of intellectual properties between tax jurisdictions, the effective income tax rates as a result of our European operations and the tax effect of future remittances of the undistributed earnings of foreign subsidiaries.
Effective Income Tax Rate Reconciliation
202120202019
United States federal statutory rate21.0 %21.0 %21.0 %
United States state and local income taxes, less federal deduction2.7 0.1 1.7 
Foreign income tax at rates other than 21%(6.9)(3.3)(4.6)
Tax related to repatriation of foreign earnings1.4 3.0 (0.5)
Intellectual property transfer(2.3)(1.4)3.5 
Other(3.3)(1.2)(2.4)
Effective income tax rate12.6 %18.2 %18.7 %
Earnings Before Income Taxes 
202120202019
United States$433 $239 $366 
International1,848 1,715 2,196 
Total$2,281 $1,954 $2,562 
Components of Income Tax Expense (Benefit)
Current income tax expense:202120202019
United States federal$155 $80 $(17)
United States state and local97 20 46 
International272 207 324 
Total current income tax expense$524 $307 $353 
Deferred income tax (benefit) expense:
United States federal$(82)$1 $10 
United States state and local(23)(25)(1)
International(132)72 117 
Total deferred income tax (benefit) expense $(237)$48 $126 
Total income tax expense$287 $355 $479 
Interest and penalties included in other income (expense), net were expense of ($23), ($35) and ($9) in 2021, 2020 and 2019. The United States federal deferred income tax benefit (expense) includes the utilization of net operating loss carryforwards of $283, $41 and $50 in 2021, 2020 and 2019.
Deferred Income Tax Assets and Liabilities
Deferred income tax assets:20212020
Inventories$513 $434 
Product-related liabilities39 48 
Other accrued expenses501 512 
Depreciation and amortization1,194 1,269 
State income taxes128 108 
Share-based compensation63 56 
Net operating loss and other credit carryforwards232 470 
Other191 166 
Total deferred income tax assets$2,861 $3,063 
Less valuation allowances(164)(203)
Net deferred income tax assets$2,697 $2,860 
Deferred income tax liabilities:20212020
Depreciation and amortization$(891)$(1,286)
Undistributed earnings(114)(161)
Total deferred income tax liabilities$(1,005)$(1,447)
Net deferred income tax assets$1,692 $1,413 
Reported as:
Noncurrent deferred income tax assets$1,760 $1,530 
Noncurrent liabilities—Other liabilities(68)(117)
Total$1,692 $1,413 
Accrued interest and penalties were $150 and $133 on December 31, 2021 and 2020 which were reported in current and noncurrent accrued expenses and other liabilities.
Net operating loss carryforwards totaling $602 with $192 being subject to a full valuation allowance ($183 and $106 related to the Wright acquisition) on December 31, 2021 are available to reduce future taxable earnings of certain domestic and foreign
subsidiaries. United States loss carryforwards of $403 expire through 2045. International loss carryforwards of $198 begin to expire in 2022; however, some have no expiration. We also have tax credit carryforwards of $104 with $83 being subject to a full valuation allowance. The credits with a full valuation allowance begin to expire in 2022; however, some have no expiration. We do not anticipate generating income tax in excess of the non-expiring credits in the foreseeable future.
The Tax Cuts and Jobs Act ("the Act") was enacted in 2017 in the United States. We recorded a one-time transition tax on earnings of certain foreign subsidiaries that were previously deferred. The Act also subjects a United States shareholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred.
We recorded deferred income tax on undistributed earnings of foreign subsidiaries not determined to be indefinitely reinvested. Determination of the total amount of unrecognized deferred income tax on undistributed earnings of foreign subsidiaries is not practicable.
Uncertain Income Tax Positions
 20212020
Beginning uncertain tax positions$457 $472 
Increases related to current year income tax positions13 12 
Increases related to prior year income tax positions4 5 
Decreases related to prior year income tax positions:
Settlements and resolutions of income tax audits(18)(41)
Statute of limitations expirations and other— (7)
Foreign currency translation(12)16 
Ending uncertain tax positions$444 $457 
Reported as:
Noncurrent liabilities—Income taxes$444 $457 
Our income tax expense would have been reduced by $445 and $456 in 2021 and 2020 had these uncertain income tax positions been favorably resolved. It is reasonably possible that the amount of unrecognized tax benefits will significantly change due to one or more of the following events in the next 12 months: expiring statutes, audit activity, tax payments, competent authority proceedings related to transfer pricing or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate, including inventory transfer pricing, cost sharing, product royalty and foreign branch arrangements. We are not able to reasonably estimate the amount or the future periods in which changes in unrecognized tax benefits may be resolved. Interest and penalties incurred associated with uncertain tax positions are included in other income (expense), net.
In the normal course of business, income tax authorities in various income tax jurisdictions both within the United States and internationally conduct routine audits of our income tax returns filed in prior years. These audits are generally designed to determine if individual income tax authorities are in agreement with our interpretations of complex income tax regulations regarding the allocation of income to the various income tax jurisdictions. Income tax years are open from 2014 through the current year for the United States federal jurisdiction. Income tax years open for our other major jurisdictions range from 2006 through the current year.
v3.22.0.1
Retirement Plans
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Retirement Plans RETIREMENT PLANS
Defined Contribution Plans
We provide certain employees with defined contribution plans and other types of retirement plans. A portion of our retirement plan expense under the defined contribution plans is funded with Stryker common stock. The use of Stryker common stock
represents a non-cash operating activity that is not reflected in our Consolidated Statements of Cash Flows.
202120202019
Plan expense$259 $235 $205 
Expense funded with Stryker common stock37 34 31 
Stryker common stock held by plan:
Dollar amount582 542 470 
Shares (in millions)2.2 2.2 2.2 
Value as a percentage of total plan assets10 %11 %12 %
Defined Benefit Plans
Certain of our subsidiaries have both funded and unfunded defined benefit pension plans covering some or all of their employees. Substantially all of the defined benefit pension plans have projected benefit obligations in excess of plan assets.
Discount Rate
The discount rates were selected using a hypothetical portfolio of high quality bonds on December 31 that would provide the necessary cash flows to match our projected benefit payments.
Expected Return on Plan Assets
The expected return on plan assets is determined by applying the target allocation in each asset category of plan investments to the anticipated return for each asset category based on historical and projected returns.
Components of Net Periodic Pension Cost
Net periodic benefit cost:202120202019
Service cost$(72)$(63)$(41)
Interest cost(7)(8)(12)
Expected return on plan assets11 13 12 
Amortization of prior service credit1 1 1 
Recognized actuarial loss(16)(13)(9)
Curtailment gain9 — — 
Net periodic benefit cost$(74)$(70)$(49)
Changes in assets and benefit obligations recognized in OCI:
Net actuarial gain (loss)$132 $(117)$(74)
Recognized net actuarial loss16 13 9 
Prior service credit and transition amount(1)(1)(1)
Curtailment gain(9)— — 
Total recognized in other comprehensive income (loss)$138 $(105)$(66)
Total recognized in net periodic benefit cost and OCI$64 $(175)$(115)
Weighted-average rates used to determine net periodic benefit cost:
Discount rate0.8 %1.0 %1.9 %
Expected return on plan assets2.5 %2.9 %3.5 %
Rate of compensation increase2.6 %2.9 %2.9 %
Weighted-average discount rate used to determine projected benefit obligations1.1 %0.8 %1.0 %
The actuarial gain (loss) for all pension plans was primarily related to a change in the discount rate used to measure the benefit obligations of those plans.
Investment Strategy
The investment strategy for our defined benefit pension plans is to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk tolerances.
20212020
Fair value of plan assets$543 $522 
Benefit obligations(1,036)(1,118)
Funded status$(493)$(596)
Reported as:
Current liabilities—accrued compensation$(2)$(2)
Noncurrent liabilities—other liabilities(491)(594)
Pre-tax amounts recognized in AOCI:
Unrecognized net actuarial loss(215)(354)
Unrecognized prior service credit7 8 
Total$(208)$(346)
Change in Benefit Obligations
20212020
Beginning projected benefit obligations$1,118 $869 
Service cost72 63 
Interest cost7 8 
Foreign exchange impact(70)80 
Employee contributions8 8 
Actuarial (gains) losses(71)110 
Curtailment gain(23)— 
Benefits paid(5)(20)
Ending projected benefit obligations$1,036 $1,118 
Ending accumulated benefit obligations$987 $1,056 
Change in Plan Assets
20212020
Beginning fair value of plan assets$522 $428 
Actual return17 30 
Employer contributions33 33 
Employee contributions8 8 
Foreign exchange impact(29)37 
Benefits paid(8)(14)
Ending fair value of plan assets$543 $522 
Allocation of Plan Assets
2022 Target2021 Actual2020 Actual
Equity securities23 %23 %23 %
Debt securities39 41 44 
Other38 36 33 
Total100 %100 %100 %
Valuation of Plan Assets
2021Level 1Level 2Level 3Total
Cash and cash equivalents$21 $— $— $21 
Equity securities28 119 — 147 
Corporate debt securities
2 202 — 204 
Other4 68 99 171 
Total$55 $389 $99 $543 
2020
Cash and cash equivalents$14 $— $— $14 
Equity securities23 108 — 131 
Corporate debt securities2 201 — 203 
Other7 63 104 174 
Total$46 $372 $104 $522 
Our Level 3 pension plan assets consist primarily of guaranteed investment contracts with insurance companies. The insurance contracts guarantee us principal repayment and a fixed rate of return. The $5 decrease in Level 3 pension plan assets is primarily driven by the change in the corresponding pension liability. We expect to contribute $21 to our defined benefit pension plans in 2022.
Estimated Future Benefit Payments
202220232024202520262027-2031
$21 $21 $27 $22 $23 $138 
v3.22.0.1
Summary of Quarterly Data (Unaudited)
 12 Months Ended
Dec. 31, 2021
Quarterly Financial Data [Abstract]  
Summary of Quarterly Data (Unaudited) SUMMARY OF QUARTERLY DATA (UNAUDITED)
2021 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$3,953 $4,294 $4,160 $4,701 
Gross profit2,509 2,772 2,642 3,045 
Earnings (loss) before income taxes367 662 495 757 
Net earnings (loss)302 592 438 662 
Net earnings (loss) per share of common stock:
Basic$0.80 $1.57 $1.17 $1.75 
Diluted$0.79 $1.55 $1.14 $1.73 
Dividends declared per share of common stock$0.630 $0.630 $0.630 $0.695 
2020 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$3,588 $2,764 $3,737 $4,262 
Gross profit2,331 1,548 2,461 2,717 
Earnings before income taxes590 (87)780 671 
Net earnings493 (83)621 568 
Net earnings per share of common stock:
Basic$1.32 $(0.22)$1.66 $1.51 
Diluted$1.30 $(0.22)$1.63 $1.49 
Dividends declared per share of common stock$0.575 $0.575 $0.575 $0.630 
v3.22.0.1
Segment and Geographic Data
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment and Geographic Data SEGMENT AND GEOGRAPHIC DATA
Effective December 31, 2021 we segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine. This change realigns the Company's reportable business segments to its new internal reporting structure and how the Company manages its businesses as a result of the transition of responsibilities of our President and Chief Operating Officer, and the division of responsibilities between Group President, MedSurg and Neurotechnology, and Group President, Orthopaedics and Spine, in the fourth quarter of 2021. We have reflected these changes in all historical periods presented.
The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants.
Segment Results202120202019
MedSurg and Neurotechnology$9,538 $8,345 $8,475 
Orthopaedics and Spine7,570 6,006 6,409 
Net sales$17,108 $14,351 $14,884 
MedSurg and Neurotechnology$518 $496 $488 
Orthopaedics and Spine629 458 457 
Segment depreciation and amortization $1,147 $954 $945 
Corporate and Other125 122 99 
Total depreciation and amortization$1,272 $1,076 $1,044 
MedSurg and Neurotechnology$2,807 $2,414 $2,304 
Orthopaedics and Spine2,180 1,588 2,084 
Segment operating income$4,987 $4,002 $4,388 
Items not allocated to segments:
Corporate and Other$(605)$(503)$(480)
Acquisition and integration-related charges(585)(242)(275)
Amortization of intangible assets(619)(472)(464)
Restructuring-related and other charges(386)(458)(226)
Medical device regulations(107)(81)(62)
Recall-related matters(103)(17)(192)
Regulatory and legal matters2 (6)24 
Consolidated operating income$2,584 $2,223 $2,713 
Segment Assets and Capital Spending
Assets:202120202019
MedSurg and Neurotechnology$15,218 $15,250 $16,270 
Orthopaedics and Spine18,149 18,090 12,527 
Total segment assets$33,367 $33,340 $28,797 
Corporate and Other1,264 990 1,370 
Total assets$34,631 $34,330 $30,167 
Purchases of property, plant and equipment:
MedSurg and Neurotechnology$197 $192 $281 
Orthopaedics and Spine165 150 138 
Total segment purchases of property, plant and equipment$362 $342 $419 
Corporate and Other163 145 230 
Total purchases of property, plant and equipment$525 $487 $649 
We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, restructuring-related charges, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally property, plant and equipment and noncurrent assets.
The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based on the geographic area of the Stryker location where the sales to the customer originated.
Geographic Information
Net SalesNet Property, Plant and Equipment
20212020201920212020
United States$12,321 $10,455 $10,957 $1,717 $1,645 
Europe, Middle East, Africa2,299 1,818 1,888 941 938 
Asia Pacific1,973 1,630 1,617 76 91 
Other countries515 448 422 99 78 
Total$17,108 $14,351 $14,884 $2,833 $2,752 
v3.22.0.1
Asset Impairments
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Asset Impairments ASSET IMPAIRMENTS
The government in China has launched regional and national programs for volume-based procurement ("VBP") of high-value medical consumables to reduce healthcare costs. Each VBP program has specific requirements to award contracts to the lowest bidders who are able to satisfy the quality and quantity requirements. The successful bidders may be guaranteed sales volume for certain products, while unsuccessful bidders may lose unit sales volume. We expect that the prices required for a successful bid will, nevertheless, negatively impact our existing commercial operations of joint replacement and trauma products in China. As a result of the outcome of certain regional programs for our trauma products and the national VBP program for hips and knees we recorded charges of $105 to impair certain long-lived and intangible assets in the third quarter of 2021. These charges were included in selling, general and administrative expenses. Spine products are part of the VBP program in one province and it is not clear to what extent spine products will be included in further provincial or national VBP programs. We do not expect any significant impairments related to the potential Spine VBP programs. Our business in China represented approximately 2.5% of our revenues for the year ended December 31, 2021.
Aside from the impairments from the VBP programs, we recorded asset impairments of $159 in 2021 consisting primarily of in-
process research and development, other intangible assets and property, plant and equipment as a result of COVID-19-related demand impacts on in-process product development and certain other divestiture and restructuring activities. In 2020 we suspended certain in-process investments resulting in charges of $195 to impair certain long-lived assets (primarily the portion of our investment in a new global ERP system that was in-process of being developed for future deployment) and product line and other exit costs. These charges were included in cost of sales and selling, general and administrative expenses
v3.22.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Significant Accounting Policies [Abstract]  
Nature of Operations Stryker (the "Company," "we," "us," or "our") is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties.
Basis of Presentation and Consolidation The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities and none that require consolidation. Prior years' segment results have been reclassified to conform with current year presentation in our Consolidated Financial Statements.
Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of net sales and expenses in the reporting period. Actual results could differ from those estimates.
Revenue Recognition Sales are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. Our sales are recognized primarily when we transfer control to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time.
Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality.
A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales returns has been established based on contract terms with our customers and historical business practices and current trends. Shipping and handling costs charged to customers are included in net sales.
Cost of Sales Cost of sales is primarily comprised of direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity.
Research, Development and Engineering Expenses Research, development and engineering costs are charged to expense as incurred. Costs include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment.
Selling, General and Administrative Expenses Selling, general and administrative expense is primarily comprised of selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items.
Currency Translation Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States Dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in other income (expense), net.
Cash Equivalents Highly liquid investments with remaining stated maturities of three months or less when purchased or other money market instruments that are redeemable upon demand are considered cash equivalents and recorded at cost.
Marketable Securities Marketable securities consist of marketable debt securities, certificates of deposit and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities and are recognized in other noncurrent assets. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Investments in trading securities represent participant-directed investments of deferred employee compensation.
Accounts Receivable Accounts receivable consists of trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience, current market conditions and expected credit losses. Accounts receivable are written off when all reasonable collection efforts are exhausted.
Inventories Inventories are stated at the lower of cost or net realizable value, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to net realizable value.
Financial Instruments Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2021 and 2020. Refer to Notes 3 and 10 for further details.
All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recognized as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recognized in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method.
We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI.
Derivatives All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period.
Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. These nonfunctional currency exposures principally relate to forecasted intercompany sales and purchases of manufactured products and generally have maturities up to eighteen months. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in cost of goods sold in the Consolidated Statements of Earnings. Cash flows associated with these hedges are included in cash from operations in the same category as the cash flows from the items being hedged.
Forward currency exchange contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities, primarily intercompany payables and receivables. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the
measurement of the contracts at month-end spot rates as adjusted by current forward points.
From time to time, we designate derivative and non-derivative financial instruments as net investment hedges of our investments in certain international subsidiaries. For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is recognized in OCI and reported as a component of AOCI. We have elected to use the spot method to assess effectiveness for our derivatives designated as net investment hedges. Accordingly, the change in fair value attributable to changes in the spot rate is recorded in AOCI. We exclude the spot-forward difference from the assessment of hedge effectiveness and amortize this amount separately on a straight-line basis over the term of the forward contracts. This amortization is recognized in other income (expense), net.
From time to time, we designate forward starting interest rate derivative instruments as cash flow hedges to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in interest expense in the Consolidated Statements of Earnings.
Interest rate derivative instruments designated as fair value hedges have been used in the past to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.
Property, Plant and Equipment Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three to 30 years for buildings and improvements and three to 15 years for machinery and equipment.
Goodwill and Other Intangible Assets Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio.
The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four to 40 years. Certain acquired trade names are considered to have indefinite lives and are not amortized, but are assessed annually for potential impairment as described below.
In some of our acquisitions, we acquire in-process research and development (IPRD) intangible assets. For acquisitions accounted for as business combinations IPRD is considered to
be an indefinite-lived intangible asset until the research is completed (then it becomes a determinable-lived intangible asset) or determined to have no future use (then it is impaired). For asset acquisitions IPRD is expensed immediately unless there is an alternative future use.
Goodwill, Intangibles and Long-Lived Asset Impairment Tests We perform our annual impairment test for goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill and periodically corroborate that assessment with quantitative information. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value.We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale are recorded at the lower of carrying amount or fair value less costs to sell.
Share-Based Compensation hare-based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long-term incentive plans to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments.
We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals in that three-year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant.
Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to
determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.
Income Taxes Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities in the year. Other amounts result from adjustments related to acquisitions and foreign currency as appropriate.We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.
New Accounting Pronouncements Not Yet Adopted and Accounting Pronouncements Recently Adopted
New Accounting Pronouncements Not Yet Adopted
In October 2021 the Financial Accounting Standards Board issued Accounting Standards Update 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers. We are evaluating the impact this update will have on our Consolidated Financial Statements.
Accounting Pronouncements Recently Adopted
No new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our Consolidated Financial Statements.
v3.22.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue Recognition [Abstract]  
Schedule of Disaggregated Revenue
Segment Net Sales
MedSurg and Neurotechnology:202120202019
Instruments$2,111 $1,863 $1,959 
Endoscopy2,141 1,763 1,983 
Medical2,607 2,524 2,264 
Neurovascular1,188 973 924 
Neuro Cranial1,214 972 1,059 
Other277 250 286 
$9,538 $8,345 $8,475 
Orthopaedics and Spine:
Knees$1,848 $1,567 $1,815 
Hips1,342 1,206 1,383 
Trauma and Extremities2,664 1,722 1,639 
Spine1,167 1,047 1,157 
Other549 464 415 
$7,570 $6,006 $6,409 
Total$17,108 $14,351 $14,884 
United States Net Sales
MedSurg and Neurotechnology:202120202019
Instruments$1,637 $1,471 $1,542 
Endoscopy1,670 1,408 1,577 
Medical2,007 1,910 1,787 
Neurovascular451 381 391 
Neuro Cranial988 801 890 
Other273 247 283 
$7,026 $6,218 $6,470 
Orthopaedics and Spine:
Knees$1,351 $1,170 $1,347 
Hips822 777 882 
Trauma and Extremities1,866 1,139 1,051 
Spine831 764 873 
Other425 387 334 
$5,295 $4,237 $4,487 
Total$12,321 $10,455 $10,957 
International Net Sales
MedSurg and Neurotechnology:202120202019
Instruments$474 $392 $417 
Endoscopy471 355 406 
Medical600 614 477 
Neurovascular737 592 533 
Neuro Cranial226 171 169 
Other4 3 3 
$2,512 $2,127 $2,005 
Orthopaedics and Spine:
Knees$497 $397 $468 
Hips520 429 501 
Trauma and Extremities798 583 588 
Spine336 283 284 
Other124 77 81 
$2,275 $1,769 $1,922 
Total$4,787 $3,896 $3,927 
v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets Measured at Fair Value
20212020
Cash and cash equivalents$2,944 $2,943 
Trading marketable securities193 171 
Level 1 - Assets$3,137 $3,114 
Available-for-sale marketable securities:
Corporate and asset-backed debt securities$48 $38 
Foreign government debt securities2 — 
United States agency debt securities5 5 
United States treasury debt securities19 36 
Certificates of deposit1 2 
Total available-for-sale marketable securities$75 $81 
Foreign currency exchange forward contracts212 20 
Level 2 - Assets$287 $101 
Total assets measured at fair value$3,424 $3,215 
Liabilities Measured at Fair Value
20212020
Deferred compensation arrangements$193 $171 
Level 1 - Liabilities$193 $171 
Foreign currency exchange forward contracts$17 $160 
Interest rate swap liability— 53 
Level 2 - Liabilities$17 $213 
Contingent consideration:
Beginning$393 $306 
Additions62 108 
Change in estimate (1)9 
Settlements(148)(30)
Ending$306 $393 
Level 3 - Liabilities$306 $393 
Total liabilities measured at fair value$516 $777 
Available-for-sale Securities
Fair Value of Available for Sale Securities by Maturity
20212020
Due in one year or less$36 $42 
Due after one year through three years$39 $39 
v3.22.0.1
Derivative Instruments (Tables)
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
2021Cash FlowNet InvestmentNon-DesignatedTotal
Gross notional amount$973 $2,266 $5,512 $8,751 
Maximum term in years4.9
Fair value:
Other current assets$15 $39 $92 $146 
Other noncurrent assets1 65 — 66 
Other current liabilities(7)— (10)(17)
Total fair value$9 $104 $82 $195 
2020
Gross notional amount$949 $1,828 $5,382 $8,159 
Maximum term in years4.9
Fair value:
Other current assets$9 $— $7 $16 
Other noncurrent assets— 4 — 4 
Other current liabilities(12)— (121)(133)
Other noncurrent liabilities(1)(26)— (27)
Total fair value$(4)$(22)$(114)$(140)
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location
Net Currency Exchange Rate Gains (Losses)
Derivative InstrumentRecorded in:202120202019
Cash FlowCost of sales$(12)$5 $2 
Net InvestmentOther income (expense), net35 28 14 
Non-DesignatedOther income (expense), net(10)(13)(7)
Total$13 $20 $9 
v3.22.0.1
Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)
 12 Months Ended
Dec. 31, 2021
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Marketable SecuritiesPension PlansHedgesFinancial Statement TranslationTotal
2019$(3)$(179)$47 $(471)$(606)
OCI— (117)(64)(459)(640)
Income taxes— 28 17 66 111 
Reclassifications to:
Cost of Sales— — (5)— (5)
Other (income) expense, net— 12 (6)(28)(22)
Income taxes— (3)1 7 5 
Net OCI— (80)(57)(414)(551)
2020$(3)$(259)$(10)$(885)$(1,157)
OCI4 123 46 551 724 
Income taxes— (32)(15)(54)(101)
Reclassifications to:
Cost of Sales— — 12 — 12 
Other (income) expense, net— 15 6 (35)(14)
Income taxes(1)(2)1 7 5 
Net OCI3 104 50 469 626 
2021$— $(155)$40 $(416)$(531)
v3.22.0.1
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2021
Business Combinations [Abstract]  
Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions
Purchase price allocations for our significant acquisitions are:
Purchase Price Allocation of Acquired Net Assets
2020Wright
Tangible assets acquired:
Accounts receivable$127 
Deferred income tax assets491 
Inventory440 
Other assets343 
Debt(1,446)
Deferred income tax liabilities(503)
Product liabilities(218)
Other liabilities(296)
Intangible assets:
Customer and distributor relationships182 
Developed technology and patents1,506 
Trade name58 
Goodwill3,397 
Purchase price, net of cash acquired$4,081 
Weighted average life of intangible assets12
v3.22.0.1
Contingencies and Commitments (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Lease, Cost
20212020
Right-of-use assets $419 $423 
Lease liabilities, current $112 $109 
Lease liabilities, noncurrent $310 $325 
Other information:
Weighted-average remaining lease term 5.4 years5.6 years
Weighted-average discount rate2.86 %2.57 %
Future Purchase Obligations and Minimum Lease Payments
20222023202420252026Thereafter
Debt repayments$7 $1,226 $1,564 $1,400 $1,000 $7,392 
Purchase obligations$1,889 $69 $54 $46 $49 $— 
Minimum lease payments$112 $86 $60 $38 $34 $72 
v3.22.0.1
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the Net Carrying Amount of Goodwill by Segment
Changes in the Net Carrying Value of Goodwill by Segment
MedSurg and NeurotechnologyOrthopaedics and SpineTotal
2019$5,377 $3,692 $9,069 
Additions and adjustments1 3,558 3,559 
Foreign exchange81 69 150 
2020$5,459 $7,319 $12,778 
Additions and adjustments223 59 282 
Foreign exchange(13)(129)(142)
2021$5,669 $7,249 $12,918 
Summary of the Company's Other Intangible Assets
Summary of Other Intangible Assets
Weighted Average Amortization Period (Years)Gross
Carrying
Amount		Less
Accumulated
Amortization		Net
Carrying
Amount
Developed technologies
202113$5,326 $1,956 $3,370 
2020135,305 1,573 3,732 
Customer relationships
202115$2,324 $1,174 $1,150 
2020152,352 988 1,364 
Patents
202112$343 $286 $57 
202012346 278 68 
Trademarks
202116$415 $199 $216 
202017428 162 266 
In-process research and development
2021N/A$29 $— $29 
2020N/A97 — 97 
Other
20219$105 $87 $18 
20208128 101 27 
Total
202114$8,542 $3,702 $4,840 
2020148,656 3,102 5,554 
Estimated Amortization Expense
Estimated Amortization Expense
20222023202420252026
$581 $558 $528 $506 $447 
v3.22.0.1
Capital Stock (Tables)
 12 Months Ended
Dec. 31, 2021
Capital Stock [Abstract]  
Schedule of Fair Value Assumptions
Option Value and Assumptions
202120202019
Weighted-average fair value per share$53.35 $39.34 $36.30 
Assumptions:
Risk-free interest rate0.8 %1.4 %2.6 %
Expected dividend yield1.2 %1.0 %1.1 %
Expected stock price volatility26.9 %18.9 %18.3 %
Expected option life (years)5.95.85.9
Summary of Stock Option Activity
2021 Stock Option Activity
Shares
(in millions)		Weighted
Average
Exercise Price		Weighted-Average
Remaining
Term (in years)		Aggregate
Intrinsic
 Value
Outstanding January 112.2 $131.72 
Granted1.8 235.35 
Exercised(1.6)96.41 
Canceled or forfeited(0.3)192.60 
Outstanding December 3112.1 $150.17 5.7$1,424.2 
Exercisable December 317.1 $113.56 4.2$1,086.3 
Options expected to vest4.6 $199.41 7.7$313.3 
Summary of RSU and PSU Activity
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Activity
Shares
(in millions)		Weighted Average
Grant Date Fair Value
RSUsPSUsRSUsPSUs
Nonvested on January 10.8 0.2 $187.72 $185.46 
Granted0.4 0.1 230.61 233.95 
Vested(0.4)(0.1)179.15 153.67 
Canceled or forfeited(0.1)— 187.38 160.11 
Nonvested on December 310.7 0.2 $213.16 $210.73 
v3.22.0.1
Debt and Credit Facilities (Tables)
 12 Months Ended
Dec. 31, 2021
Long-term Debt, Unclassified [Abstract]  
Maturities Of Long-Term Debt Disclosures
Summary of Total Debt
Senior unsecured notes:
RateDue20212020
2.625%March 15, 2021$— $750 
1.125%November 30, 2023622 668 
0.600%December 1, 2023598 597 
3.375%May 15, 2024593 590 
0.250%December 3, 2024958 1,030 
1.150%June 15, 2025645 644 
3.375%November 1, 2025748 747 
3.500%March 15, 2026994 992 
2.125%November 30, 2027845 909 
3.650%March 7, 2028597 596 
0.750%March 1, 2029901 969 
1.950%June 15, 2030990 989 
2.625%November 30, 2030727 782 
1.000%December 3, 2031840 903 
4.100%April 1, 2043392 392 
4.375%May 15, 2044395 395 
4.625%March 15, 2046982 981 
2.900%June 15, 2050642 641 
Term loan— 400 
Other10 16 
Total debt$12,479 $13,991 
Less current maturities7 761 
Total long-term debt$12,472 $13,230 
Unamortized debt issuance costs$62 $71 
Borrowing capacity on existing facilities$2,162 $2,903 
Fair value of senior unsecured notes$13,391 $15,022 
v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations
Effective Income Tax Rate Reconciliation
202120202019
United States federal statutory rate21.0 %21.0 %21.0 %
United States state and local income taxes, less federal deduction2.7 0.1 1.7 
Foreign income tax at rates other than 21%(6.9)(3.3)(4.6)
Tax related to repatriation of foreign earnings1.4 3.0 (0.5)
Intellectual property transfer(2.3)(1.4)3.5 
Other(3.3)(1.2)(2.4)
Effective income tax rate12.6 %18.2 %18.7 %
Schedule of Provision for Income Taxes
Earnings Before Income Taxes 
202120202019
United States$433 $239 $366 
International1,848 1,715 2,196 
Total$2,281 $1,954 $2,562 
Components of Income Tax Expense (Benefit)
Current income tax expense:202120202019
United States federal$155 $80 $(17)
United States state and local97 20 46 
International272 207 324 
Total current income tax expense$524 $307 $353 
Deferred income tax (benefit) expense:
United States federal$(82)$1 $10 
United States state and local(23)(25)(1)
International(132)72 117 
Total deferred income tax (benefit) expense $(237)$48 $126 
Total income tax expense$287 $355 $479 
Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities
Deferred Income Tax Assets and Liabilities
Deferred income tax assets:20212020
Inventories$513 $434 
Product-related liabilities39 48 
Other accrued expenses501 512 
Depreciation and amortization1,194 1,269 
State income taxes128 108 
Share-based compensation63 56 
Net operating loss and other credit carryforwards232 470 
Other191 166 
Total deferred income tax assets$2,861 $3,063 
Less valuation allowances(164)(203)
Net deferred income tax assets$2,697 $2,860 
Deferred income tax liabilities:20212020
Depreciation and amortization$(891)$(1,286)
Undistributed earnings(114)(161)
Total deferred income tax liabilities$(1,005)$(1,447)
Net deferred income tax assets$1,692 $1,413 
Reported as:
Noncurrent deferred income tax assets$1,760 $1,530 
Noncurrent liabilities—Other liabilities(68)(117)
Total$1,692 $1,413 
Schedule of Unresolved Income Tax Positions
Uncertain Income Tax Positions
 20212020
Beginning uncertain tax positions$457 $472 
Increases related to current year income tax positions13 12 
Increases related to prior year income tax positions4 5 
Decreases related to prior year income tax positions:
Settlements and resolutions of income tax audits(18)(41)
Statute of limitations expirations and other— (7)
Foreign currency translation(12)16 
Ending uncertain tax positions$444 $457 
Reported as:
Noncurrent liabilities—Income taxes$444 $457 
v3.22.0.1
Retirement Plans (Tables)
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Defined Contribution Plan Disclosures
202120202019
Plan expense$259 $235 $205 
Expense funded with Stryker common stock37 34 31 
Stryker common stock held by plan:
Dollar amount582 542 470 
Shares (in millions)2.2 2.2 2.2 
Value as a percentage of total plan assets10 %11 %12 %
Schedule of Costs of Retirement Plans
Components of Net Periodic Pension Cost
Net periodic benefit cost:202120202019
Service cost$(72)$(63)$(41)
Interest cost(7)(8)(12)
Expected return on plan assets11 13 12 
Amortization of prior service credit1 1 1 
Recognized actuarial loss(16)(13)(9)
Curtailment gain9 — — 
Net periodic benefit cost$(74)$(70)$(49)
Changes in assets and benefit obligations recognized in OCI:
Net actuarial gain (loss)$132 $(117)$(74)
Recognized net actuarial loss16 13 9 
Prior service credit and transition amount(1)(1)(1)
Curtailment gain(9)— — 
Total recognized in other comprehensive income (loss)$138 $(105)$(66)
Total recognized in net periodic benefit cost and OCI$64 $(175)$(115)
Weighted-average rates used to determine net periodic benefit cost:
Discount rate0.8 %1.0 %1.9 %
Expected return on plan assets2.5 %2.9 %3.5 %
Rate of compensation increase2.6 %2.9 %2.9 %
Weighted-average discount rate used to determine projected benefit obligations1.1 %0.8 %1.0 %
Schedule of Defined Benefit Plans Disclosures
20212020
Fair value of plan assets$543 $522 
Benefit obligations(1,036)(1,118)
Funded status$(493)$(596)
Reported as:
Current liabilities—accrued compensation$(2)$(2)
Noncurrent liabilities—other liabilities(491)(594)
Pre-tax amounts recognized in AOCI:
Unrecognized net actuarial loss(215)(354)
Unrecognized prior service credit7 8 
Total$(208)$(346)
Schedule of Changes in Accumulated Postemployment Benefit Obligations
Change in Benefit Obligations
20212020
Beginning projected benefit obligations$1,118 $869 
Service cost72 63 
Interest cost7 8 
Foreign exchange impact(70)80 
Employee contributions8 8 
Actuarial (gains) losses(71)110 
Curtailment gain(23)— 
Benefits paid(5)(20)
Ending projected benefit obligations$1,036 $1,118 
Ending accumulated benefit obligations$987 $1,056 
Schedule of Changes in Fair Value of Plan Assets
Change in Plan Assets
20212020
Beginning fair value of plan assets$522 $428 
Actual return17 30 
Employer contributions33 33 
Employee contributions8 8 
Foreign exchange impact(29)37 
Benefits paid(8)(14)
Ending fair value of plan assets$543 $522 
Valuation of Plan Assets
2021Level 1Level 2Level 3Total
Cash and cash equivalents$21 $— $— $21 
Equity securities28 119 — 147 
Corporate debt securities
2 202 — 204 
Other4 68 99 171 
Total$55 $389 $99 $543 
2020
Cash and cash equivalents$14 $— $— $14 
Equity securities23 108 — 131 
Corporate debt securities2 201 — 203 
Other7 63 104 174 
Total$46 $372 $104 $522 
Schedule of Allocation of Plan Assets
Allocation of Plan Assets
2022 Target2021 Actual2020 Actual
Equity securities23 %23 %23 %
Debt securities39 41 44 
Other38 36 33 
Total100 %100 %100 %
Schedule of Expected Benefit Payments
Estimated Future Benefit Payments
202220232024202520262027-2031
$21 $21 $27 $22 $23 $138 
v3.22.0.1
Summary of Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2021
Quarterly Financial Data [Abstract]  
Summary of Quarterly Data
2021 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$3,953 $4,294 $4,160 $4,701 
Gross profit2,509 2,772 2,642 3,045 
Earnings (loss) before income taxes367 662 495 757 
Net earnings (loss)302 592 438 662 
Net earnings (loss) per share of common stock:
Basic$0.80 $1.57 $1.17 $1.75 
Diluted$0.79 $1.55 $1.14 $1.73 
Dividends declared per share of common stock$0.630 $0.630 $0.630 $0.695 
2020 QuartersMar 31Jun 30Sep 30Dec 31
Net sales$3,588 $2,764 $3,737 $4,262 
Gross profit2,331 1,548 2,461 2,717 
Earnings before income taxes590 (87)780 671 
Net earnings493 (83)621 568 
Net earnings per share of common stock:
Basic$1.32 $(0.22)$1.66 $1.51 
Diluted$1.30 $(0.22)$1.63 $1.49 
Dividends declared per share of common stock$0.575 $0.575 $0.575 $0.630 
v3.22.0.1
Segment and Geographic Data (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Segment Results202120202019
MedSurg and Neurotechnology$9,538 $8,345 $8,475 
Orthopaedics and Spine7,570 6,006 6,409 
Net sales$17,108 $14,351 $14,884 
MedSurg and Neurotechnology$518 $496 $488 
Orthopaedics and Spine629 458 457 
Segment depreciation and amortization $1,147 $954 $945 
Corporate and Other125 122 99 
Total depreciation and amortization$1,272 $1,076 $1,044 
MedSurg and Neurotechnology$2,807 $2,414 $2,304 
Orthopaedics and Spine2,180 1,588 2,084 
Segment operating income$4,987 $4,002 $4,388 
Items not allocated to segments:
Corporate and Other$(605)$(503)$(480)
Acquisition and integration-related charges(585)(242)(275)
Amortization of intangible assets(619)(472)(464)
Restructuring-related and other charges(386)(458)(226)
Medical device regulations(107)(81)(62)
Recall-related matters(103)(17)(192)
Regulatory and legal matters2 (6)24 
Consolidated operating income$2,584 $2,223 $2,713 
Sales and Other Financial Information by Business Segment
Segment Assets and Capital Spending
Assets:202120202019
MedSurg and Neurotechnology$15,218 $15,250 $16,270 
Orthopaedics and Spine18,149 18,090 12,527 
Total segment assets$33,367 $33,340 $28,797 
Corporate and Other1,264 990 1,370 
Total assets$34,631 $34,330 $30,167 
Purchases of property, plant and equipment:
MedSurg and Neurotechnology$197 $192 $281 
Orthopaedics and Spine165 150 138 
Total segment purchases of property, plant and equipment$362 $342 $419 
Corporate and Other163 145 230 
Total purchases of property, plant and equipment$525 $487 $649 
Geographic Information on Net Sales and Long-Lived Assets
Geographic Information
Net SalesNet Property, Plant and Equipment
20212020201920212020
United States$12,321 $10,455 $10,957 $1,717 $1,645 
Europe, Middle East, Africa2,299 1,818 1,888 941 938 
Asia Pacific1,973 1,630 1,617 76 91 
Other countries515 448 422 99 78 
Total$17,108 $14,351 $14,884 $2,833 $2,752 
v3.22.0.1
Significant Accounting Policies (Narrative) (Details)
 12 Months Ended
Dec. 31, 2021
Employee Stock Option  
Vesting period 10 years
Restricted Stock Units (RSUs)  
Performance period 3 years
Performance Stock Units (PSUs)  
Vesting period 3 years
Minimum  
Finite-lived intangible asset, useful life 4 years
Maximum  
Finite-lived intangible asset, useful life 40 years
Building and Improvements | Minimum  
Property, plant and equipment useful life 3 years
Building and Improvements | Maximum  
Property, plant and equipment useful life 30 years
Machinery and Equipment | Minimum  
Property, plant and equipment useful life 3 years
Machinery and Equipment | Maximum  
Property, plant and equipment useful life 15 years
v3.22.0.1
Revenue Recognition - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue Recognition [Abstract]    
Percentage of sales recognized as services over time (less than) 10.00%  
Contract liabilities $ 529 $ 416
v3.22.0.1
Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]                      
Net sales $ 4,701,000 $ 4,160,000 $ 4,294,000 $ 3,953,000 $ 4,262,000 $ 3,737,000 $ 2,764,000 $ 3,588,000 $ 17,108,000 $ 14,351,000 $ 14,884,000
United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 12,321,000 10,455,000 10,957,000
International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 4,787,000 3,896,000 3,927,000
MedSurg and Neurotechnology                      
Disaggregation of Revenue [Line Items]                      
Net sales                 9,538,000 8,345,000 8,475,000
MedSurg and Neurotechnology | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 7,026,000 6,218,000 6,470,000
MedSurg and Neurotechnology | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,512,000 2,127,000 2,005,000
MedSurg and Neurotechnology | Instruments                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,111,000 1,863,000 1,959,000
MedSurg and Neurotechnology | Instruments | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,637,000 1,471,000 1,542,000
MedSurg and Neurotechnology | Instruments | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 474,000 392,000 417,000
MedSurg and Neurotechnology | Endoscopy                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,141,000 1,763,000 1,983,000
MedSurg and Neurotechnology | Endoscopy | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,670,000 1,408,000 1,577,000
MedSurg and Neurotechnology | Endoscopy | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 471,000 355,000 406,000
MedSurg and Neurotechnology | Medical                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,607,000 2,524,000 2,264,000
MedSurg and Neurotechnology | Medical | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,007,000 1,910,000 1,787,000
MedSurg and Neurotechnology | Medical | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 600,000 614,000 477,000
MedSurg and Neurotechnology | Neurovascular                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,188,000 973,000 924,000
MedSurg and Neurotechnology | Neurovascular | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 451,000 381,000 391,000
MedSurg and Neurotechnology | Neurovascular | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 737,000 592,000 533,000
MedSurg and Neurotechnology | Neuro Cranial                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,214,000 972,000 1,059,000
MedSurg and Neurotechnology | Neuro Cranial | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 988,000 801,000 890,000
MedSurg and Neurotechnology | Neuro Cranial | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 226,000 171,000 169,000
MedSurg and Neurotechnology | Other                      
Disaggregation of Revenue [Line Items]                      
Net sales                 277,000 250,000 286,000
MedSurg and Neurotechnology | Other | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 273,000 247,000 283,000
MedSurg and Neurotechnology | Other | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 4,000 3,000 3,000
Orthopaedics and Spine                      
Disaggregation of Revenue [Line Items]                      
Net sales                 7,570,000 6,006,000 6,409,000
Orthopaedics and Spine | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 5,295,000 4,237,000 4,487,000
Orthopaedics and Spine | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,275,000 1,769,000 1,922,000
Orthopaedics and Spine | Other                      
Disaggregation of Revenue [Line Items]                      
Net sales                 549,000 464,000 415,000
Orthopaedics and Spine | Other | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 425,000 387,000 334,000
Orthopaedics and Spine | Other | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 124,000 77,000 81,000
Orthopaedics and Spine | Knees                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,848,000 1,567,000 1,815,000
Orthopaedics and Spine | Knees | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,351,000 1,170,000 1,347,000
Orthopaedics and Spine | Knees | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 497,000 397,000 468,000
Orthopaedics and Spine | Hips                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,342,000 1,206,000 1,383,000
Orthopaedics and Spine | Hips | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 822,000 777,000 882,000
Orthopaedics and Spine | Hips | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 520,000 429,000 501,000
Orthopaedics and Spine | Trauma and Extremities                      
Disaggregation of Revenue [Line Items]                      
Net sales                 2,664,000 1,722,000 1,639,000
Orthopaedics and Spine | Trauma and Extremities | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,866,000 1,139,000 1,051,000
Orthopaedics and Spine | Trauma and Extremities | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 798,000 583,000 588,000
Orthopaedics and Spine | Spine                      
Disaggregation of Revenue [Line Items]                      
Net sales                 1,167,000 1,047,000 1,157,000
Orthopaedics and Spine | Spine | United States                      
Disaggregation of Revenue [Line Items]                      
Net sales                 831,000 764,000 873,000
Orthopaedics and Spine | Spine | International                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 336,000 $ 283,000 $ 284,000
v3.22.0.1
Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Assets    
Available-for-sale marketable securities: $ 75 $ 81
Total assets measured at fair value 3,424 3,215
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Total liabilities measured at fair value 516 777
(Level 1)    
Assets    
Available-for-sale marketable securities 2,944 2,943
Trading marketable securities 193 171
Total assets measured at fair value 3,137 3,114
Liabilities:    
Deferred compensation arrangements 193 171
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Total liabilities measured at fair value 193 171
(Level 2)    
Assets    
Total assets measured at fair value 287 101
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Total liabilities measured at fair value 17 213
(Level 2) | Foreign currency exchange forward contracts    
Assets    
Foreign currency exchange forward contracts 212 20
Interest rate swap asset 212 20
Liabilities:    
Foreign currency exchange forward contracts 17 160
(Level 2) | Interest rate swap    
Liabilities:    
Foreign currency exchange forward contracts 0 53
(Level 2) | Available-for-sale marketable securities:    
Assets    
Available-for-sale marketable securities: 75 81
(Level 2) | Available-for-sale marketable securities: | Corporate and asset-backed debt securities    
Assets    
Available-for-sale marketable securities: 48 38
(Level 2) | Available-for-sale marketable securities: | Foreign government debt securities    
Assets    
Available-for-sale marketable securities: 2 0
(Level 2) | Available-for-sale marketable securities: | United States agency debt securities    
Assets    
Available-for-sale marketable securities: 5 5
(Level 2) | Available-for-sale marketable securities: | United States treasury debt securities    
Assets    
Available-for-sale marketable securities: 19 36
(Level 2) | Available-for-sale marketable securities: | Certificates of deposit    
Assets    
Available-for-sale marketable securities: 1 2
(Level 3)    
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Beginning 393 306
Additions 62 108
Change in estimate (1) 9
Settlements (148) (30)
Ending 306 393
Total liabilities measured at fair value $ 306 $ 393
v3.22.0.1
Fair Value Measurements (Available-For-Sale Securities) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Due in one year or less $ 36 $ 42
Due after one year through three years $ 39 $ 39
v3.22.0.1
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Marketable securities, gain (loss) $ 68 $ 102 $ 155
v3.22.0.1
Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign currency exchange forward contracts
$ in Millions, € in Billions
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Derivative [Line Items]        
Notional amount $ 8,751 $ 8,159    
Maximum term 4 years 10 months 24 days 4 years 10 months 24 days    
Derivative, fair value, net $ 195 $ (140)    
Other current assets        
Derivative [Line Items]        
Derivative asset 146 16    
Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 66 4    
Other current liabilities        
Derivative [Line Items]        
Derivative liability (17) (133)    
Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability   (27)    
Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount 2,266 1,828 € 2.0 € 1.5
Derivative, fair value, net 104 (22)    
Designated as Hedging Instrument | Other current assets        
Derivative [Line Items]        
Derivative asset 39 0    
Designated as Hedging Instrument | Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 65 4    
Designated as Hedging Instrument | Other current liabilities        
Derivative [Line Items]        
Derivative liability 0 0    
Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability   (26)    
Not Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount 5,512 5,382    
Derivative, fair value, net 82 (114)    
Not Designated as Hedging Instrument | Other current assets        
Derivative [Line Items]        
Derivative asset 92 7    
Not Designated as Hedging Instrument | Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 0 0    
Not Designated as Hedging Instrument | Other current liabilities        
Derivative [Line Items]        
Derivative liability (10) (121)    
Not Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability   0    
Cash Flow Hedging | Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount 973 949    
Derivative, fair value, net 9 (4)    
Cash Flow Hedging | Designated as Hedging Instrument | Other current assets        
Derivative [Line Items]        
Derivative asset 15 9    
Cash Flow Hedging | Designated as Hedging Instrument | Other noncurrent assets        
Derivative [Line Items]        
Derivative asset 1 0    
Cash Flow Hedging | Designated as Hedging Instrument | Other current liabilities        
Derivative [Line Items]        
Derivative liability $ (7) (12)    
Cash Flow Hedging | Designated as Hedging Instrument | Other noncurrent liabilities        
Derivative [Line Items]        
Derivative liability   $ (1)    
v3.22.0.1
Derivative Instruments (Narrative) (Details)
$ in Millions, € in Billions
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Foreign currency exchange forward contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, notional amount $ 8,751   $ 8,159  
Interest rate swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Reclassification of gain (loss) from AOCI to earnings (11)      
Designated as Hedging Instrument | Foreign currency exchange forward contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, notional amount 2,266 € 2.0 $ 1,828 € 1.5
Notional amount | €   € 4.4   € 4.4
Derivative, fair value (34)      
Cash flow hedge gain (loss) to be reclassified within twelve months 9      
Net investment hedges expected to be reclassified to cost of sales and other income (expense) 37      
Designated as Hedging Instrument | Interest rate swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedge gain (loss) to be reclassified within twelve months 5      
Designated as Hedging Instrument | Cash Flow Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, notional amount $ 750      
v3.22.0.1
Derivative Instruments (Movements out of OCI) (Details) - Foreign currency exchange forward contracts - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative [Line Items]      
Foreign currency transaction gains (losses) $ 13 $ 20 $ 9
Cost of sales      
Derivative [Line Items]      
Foreign currency transaction gains (losses) (12) 5 2
Designated as Hedging Instrument      
Derivative [Line Items]      
Derivatives used in Net Investment Hedge, Gain (Loss), Reclassified to Earnings, Net of Tax 37    
Designated as Hedging Instrument | Other income (expense), net      
Derivative [Line Items]      
Foreign currency transaction gains (losses) 35 28 14
Not Designated as Hedging Instrument | Other income (expense), net      
Derivative [Line Items]      
Foreign currency transaction gains (losses) $ (10) $ (13) $ (7)
v3.22.0.1
Accumulated Other Comprehensive (Loss) Income (AOCI) (Schedule of Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period $ (1,157) $ (606)  
OCI 724 (640)  
Income taxes (101) 111  
Cost of sales 6,140 5,294 $ 5,188
Other (income) expense, net (303) (269) (151)
Income taxes 287 355 479
Other comprehensive income (loss) 626 (551) 25
Accumulated Other Comprehensive Income (Loss), End of Period (531) (1,157) (606)
Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Income taxes 5 5  
Other comprehensive income (loss) 626 (551)  
Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 12 (5)  
Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense, net      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Other (income) expense, net (14) (22)  
Marketable Securities      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period (3) (3)  
OCI 4 0  
Income taxes 0 0  
Accumulated Other Comprehensive Income (Loss), End of Period 0 (3) (3)
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Income taxes (1) 0  
Other comprehensive income (loss) 3 0  
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 0 0  
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense, net      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Other (income) expense, net 0 0  
Pension Plans      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period (259) (179)  
OCI 123 (117)  
Income taxes (32) 28  
Accumulated Other Comprehensive Income (Loss), End of Period (155) (259) (179)
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Income taxes (2) (3)  
Other comprehensive income (loss) 104 (80)  
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 0 0  
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense, net      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Other (income) expense, net 15 12  
Hedges      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period (10) 47  
OCI 46 (64)  
Income taxes (15) 17  
Accumulated Other Comprehensive Income (Loss), End of Period 40 (10) 47
Hedges | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Income taxes 1 1  
Other comprehensive income (loss) 50 (57)  
Hedges | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 12 (5)  
Hedges | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense, net      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Other (income) expense, net 6 (6)  
Financial Statement Translation      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Accumulated Other Comprehensive Income (Loss), Beginning of Period (885) (471)  
OCI 551 (459)  
Income taxes (54) 66  
Accumulated Other Comprehensive Income (Loss), End of Period (416) (885) $ (471)
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Income taxes 7 7  
Other comprehensive income (loss) 469 (414)  
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Cost of sales 0 0  
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense, net      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Other (income) expense, net $ (35) $ (28)  
v3.22.0.1
Acquisitions (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Jan. 31, 2022
Sep. 30, 2021
Dec. 31, 2020
Nov. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]              
Aggregate purchase price of acquisitions         $ 393 $ 4,304  
Repayments of long-term debt         $ 1,151 $ 2,297 $ 1,342
1.625% Convertible Notes              
Business Acquisition [Line Items]              
Stated interest rate       1.625%      
Repayments of long-term debt       $ 864      
2.25% Convertible Notes              
Business Acquisition [Line Items]              
Stated interest rate     2.25%     2.25%  
Repayments of long-term debt     $ 576        
Gauss              
Business Acquisition [Line Items]              
Aggregate purchase price of acquisitions   $ 120          
Future regulatory and commercial milestones   $ 40          
Wright              
Business Acquisition [Line Items]              
Aggregate purchase price of acquisitions       $ 4,100      
Consideration transferred, price per share (in dollars per share)       $ 30.75      
Purchase price of acquisitions, including convertible notes       $ 5,600      
Vocera | Subsequent Event              
Business Acquisition [Line Items]              
Aggregate purchase price of acquisitions $ 3,100            
Consideration transferred, price per share (in dollars per share) $ 79.25            
v3.22.0.1
Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]      
Goodwill $ 12,918 $ 12,778 $ 9,069
Weighted average life of intangible assets 14 years 14 years  
Developed technology and patents      
Business Acquisition [Line Items]      
Weighted average life of intangible assets 13 years 13 years  
Wright      
Business Acquisition [Line Items]      
Accounts receivable $ 127    
Deferred income tax assets 491    
Inventory 440    
Other assets 343    
Debt (1,446)    
Deferred income tax liabilities (503)    
Product liabilities (218)    
Other liabilities (296)    
Goodwill 3,397    
Purchase price, net of cash acquired $ 4,081    
Weighted average life of intangible assets 12 years    
Wright | Customer and distributor relationships      
Business Acquisition [Line Items]      
Intangible assets: $ 182    
Wright | Developed technology and patents      
Business Acquisition [Line Items]      
Intangible assets: 1,506    
Wright | Trade name      
Business Acquisition [Line Items]      
Intangible assets: $ 58    
v3.22.0.1
Contingencies and Commitments (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Charges during period $ 103    
Payments during period 221    
Lease expense 133 $ 130 $ 133
Minimum      
Estimate of possible loss 385    
Maximum      
Estimate of possible loss $ 520    
v3.22.0.1
Commitments and Contingencies - Lease Cost (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]    
Right-of-use assets $ 419 $ 423
Lease liabilities, current 112 109
Lease liabilities, noncurrent $ 310 $ 325
Weighted-average remaining lease term 5 years 4 months 24 days 5 years 7 months 6 days
Weighted-average discount rate 2.86% 2.57%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets, Noncurrent Other Assets, Noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other Liabilities, Current Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other noncurrent liabilities Other noncurrent liabilities
v3.22.0.1
Contingencies and Commitments (Future Purchase Obligations and Minimum Lease Payments) (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2022 $ 7
2023 1,226
2024 1,564
2025 1,400
2026 1,000
Thereafter 7,392
Purchase obligations  
2022 1,889
2023 69
2024 54
2025 46
2026 49
Thereafter 0
Minimum lease payments  
2022 112
2023 86
2024 60
2025 38
2026 34
Thereafter $ 72
v3.22.0.1
Goodwill and Other Intangible Assets (Changes in Net Carrying Amount of Goodwill by Segment) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill [Roll Forward]    
Goodwill, Beginning balance $ 12,778 $ 9,069
Additions and adjustments 282 3,559
Foreign exchange (142) 150
Goodwill, Ending balance 12,918 12,778
MedSurg and Neurotechnology    
Goodwill [Roll Forward]    
Goodwill, Beginning balance 5,459 5,377
Additions and adjustments 223 1
Foreign exchange (13) 81
Goodwill, Ending balance 5,669 5,459
Orthopaedics and Spine    
Goodwill [Roll Forward]    
Goodwill, Beginning balance 7,319 3,692
Additions and adjustments 59 3,558
Foreign exchange (129) 69
Goodwill, Ending balance $ 7,249 $ 7,319
v3.22.0.1
Goodwill and Other Intangible Assets (Summary of the Company's Other Intangible Assets) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Goodwill, impairment loss $ 0 $ 0
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Amortization Period (Years) 14 years 14 years
Gross Carrying Amount $ 8,542,000,000 $ 8,656,000,000
Less Accumulated Amortization 3,702,000,000 3,102,000,000
Net Carrying Amount $ 4,840,000,000 $ 5,554,000,000
Developed technologies    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Amortization Period (Years) 13 years 13 years
Gross Carrying Amount $ 5,326,000,000 $ 5,305,000,000
Less Accumulated Amortization 1,956,000,000 1,573,000,000
Net Carrying Amount $ 3,370,000,000 $ 3,732,000,000
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Amortization Period (Years) 15 years 15 years
Gross Carrying Amount $ 2,324,000,000 $ 2,352,000,000
Less Accumulated Amortization 1,174,000,000 988,000,000
Net Carrying Amount $ 1,150,000,000 $ 1,364,000,000
Patents    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Amortization Period (Years) 12 years 12 years
Gross Carrying Amount $ 343,000,000 $ 346,000,000
Less Accumulated Amortization 286,000,000 278,000,000
Net Carrying Amount $ 57,000,000 $ 68,000,000
Trademarks    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Amortization Period (Years) 16 years 17 years
Gross Carrying Amount $ 415,000,000 $ 428,000,000
Less Accumulated Amortization 199,000,000 162,000,000
Net Carrying Amount 216,000,000 266,000,000
In-process research and development    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 29,000,000 97,000,000
Less Accumulated Amortization 0 0
Net Carrying Amount $ 29,000,000 $ 97,000,000
Other    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Amortization Period (Years) 9 years 8 years
Gross Carrying Amount $ 105,000,000 $ 128,000,000
Less Accumulated Amortization 87,000,000 101,000,000
Net Carrying Amount $ 18,000,000 $ 27,000,000
v3.22.0.1
Goodwill and Other Intangible Assets (Estimated Amortization Expense) (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2022 $ 581
2023 558
2024 528
2025 506
2026 $ 447
v3.22.0.1
Capital Stock (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Capital Stock [Line Items]      
Common and Preferred Stock, shares authorized (in shares) 1,000,500,000    
Preferred stock, shares authorized 500,000    
Preferred stock, par per share $ 1    
Common stock, authorized (in shares) 1,000,000,000    
Common stock, par value (in dollars per share) $ 0.10 $ 0.10  
Preferred stock, outstanding (in shares) 0    
Remaining shares authorized to be repurchased $ 1,033    
Capital shares reserved for future issuance 25,000,000 28,000,000  
Aggregate intrinsic value of options exercised $ 253 $ 258 $ 294
Options exercised during period, exercise price range, lower range limit $ 53.60    
Options exercised during period, exercise price range, upper range limit $ 270.94    
Compensation cost not yet recognized $ 101    
Compensation cost not yet recognized, period for recognized 1 year 6 months    
Restricted Stock Units (RSUs)      
Capital Stock [Line Items]      
Compensation cost not yet recognized $ 71    
Compensation cost not yet recognized, period for recognized 1 year    
Weighted average grant date fair value, Granted (in dollars per share) $ 230.61 $ 208.96  
Shares vested during the period $ 63    
Performance Stock Units (PSUs)      
Capital Stock [Line Items]      
Compensation cost not yet recognized $ 18    
Compensation cost not yet recognized, period for recognized 1 year    
Weighted average grant date fair value, Granted (in dollars per share) $ 233.95    
Shares vested during the period $ 5    
Employee Stock Purchase Plans      
Capital Stock [Line Items]      
Percentage of closing stock price under ESPP 95.00%    
Shares issued under the ESPP 183,964 209,837  
v3.22.0.1
Capital Stock (Option Grant Assumptions) (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Capital Stock [Abstract]      
Weighted-average fair value per share $ 53.35 $ 39.34 $ 36.30
Risk-free interest rate 0.80% 1.40% 2.60%
Expected dividend yield 1.20% 1.00% 1.10%
Expected stock price volatility 26.90% 18.90% 18.30%
Expected option life (years) 5 years 10 months 24 days 5 years 9 months 18 days 5 years 10 months 24 days
v3.22.0.1
Capital Stock (Summary of Stock Option Activity) (Details)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Shares, Options outstanding at January 1 (in shares) | shares 12.2
Shares, Granted (in shares) | shares 1.8
Shares, Exercised (in shares) | shares (1.6)
Shares, Cancelled or forfeited (in shares) | shares (0.3)
Shares, Options outstanding at December 31 (in shares) | shares 12.1
Shares, Exercisable at December 31 (in shares) | shares 7.1
Shares, Options expected to vest (in shares) | shares 4.6
Weighted Average Exercise Price  
Weighted average exercise price, Options outstanding at January 1 (in dollars per share) | $ / shares $ 131.72
Weighted average exercise price, Granted (in dollars per share) | $ / shares 235.35
Weighted average exercise price, Exercised (in dollars per share) | $ / shares 96.41
Weighted average exercise price, Cancelled or forfeited (in dollars per share) | $ / shares 192.60
Weighted average exercise price, Options outstanding at December 31 (in dollars per share) | $ / shares 150.17
Weighted average exercise price, Exercisable at December 31 (in dollars per share) | $ / shares 113.56
Weighted average exercise price, Options expected to vest (in dollars per share) | $ / shares $ 199.41
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Weighted-average remaining contractual term, Options outstanding at December 31 (in years) 5 years 8 months 12 days
Weighted-average remaining contractual term, Exercisable at December 31 (in years) 4 years 2 months 12 days
Weighted-average remaining contractual term, Options expected to vest (in years) 7 years 8 months 12 days
Aggregate intrinsic value, Options outstanding at December 31 | $ $ 1,424.2
Aggregate intrinsic value, Exercisable at December 31 | $ 1,086.3
Aggregate intrinsic value, Options expected to vest | $ $ 313.3
v3.22.0.1
Capital Stock (Summary of RSU and PSU Activity) (Details) - $ / shares
shares in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Shares, Nonvested at January 1 (in shares) 0.8  
Shares, Granted (in shares) 0.4  
Shares, Vested (in shares) (0.4)  
Shares, Cancelled (in shares) (0.1)  
Shares, Nonvested at December 31 (in shares) 0.7 0.8
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share) $ 187.72  
Weighted average grant date fair value, Granted (in dollars per share) 230.61 $ 208.96
Weighted average grant date fair value, Vested (in dollars per share) 179.15  
Weighted average grant date fair value, Cancelled (in dollars per share) 187.38  
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share) $ 213.16 $ 187.72
Performance Stock Units (PSUs)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Shares, Nonvested at January 1 (in shares) 0.2  
Shares, Granted (in shares) 0.1  
Shares, Vested (in shares) (0.1)  
Shares, Cancelled (in shares) 0.0  
Shares, Nonvested at December 31 (in shares) 0.2 0.2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share) $ 185.46  
Weighted average grant date fair value, Granted (in dollars per share) 233.95  
Weighted average grant date fair value, Vested (in dollars per share) 153.67  
Weighted average grant date fair value, Cancelled (in dollars per share) 160.11  
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share) $ 210.73 $ 185.46
v3.22.0.1
Debt and Credit Facilities (Narrative) (Details)
 1 Months Ended 12 Months Ended
Oct. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Line of Credit Facility [Line Items]              
Commercial paper   $ 0          
Interest expense, debt   337,000,000 $ 315,000,000 $ 287,000,000      
Credit Agreement | Revolving Credit Facility              
Line of Credit Facility [Line Items]              
Increase in line of credit facility, maximum borrowing capacity $ 750,000,000            
Maximum borrowing capacity $ 2,250,000,000            
Leverage ratio 3.75            
Commercial Paper              
Line of Credit Facility [Line Items]              
Maximum borrowing capacity   $ 1,500,000,000          
Maturities of time deposits   397 days          
Commercial Paper | Subsequent Event              
Line of Credit Facility [Line Items]              
Maximum borrowing capacity         $ 2,250,000,000    
Senior Unsecured Notes 2.625% due 2021              
Line of Credit Facility [Line Items]              
Debt instrument, repurchased face amount             $ 750,000,000
Stated interest rate   2.625%         2.625%
Senior Unsecured Notes, 1.125% Due 2021              
Line of Credit Facility [Line Items]              
Debt instrument, repurchased face amount           $ 400,000,000  
v3.22.0.1
Debt and Credit Facilities (Maturities Of Long-Term Debt Disclosures) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Other long-term debt $ 10   $ 16
Total debt 12,479   13,991
Current maturities of debt 7   761
Total long-term debt 12,472   13,230
Unamortized debt issuance costs 62   71
Borrowing capacity on existing facilities 2,162   2,903
Fair value of senior unsecured notes $ 13,391   15,022
Senior Unsecured Notes 2.625% due 2021      
Stated interest rate 2.625% 2.625%  
Unsecured debt $ 0   750
Senior Unsecured Notes, 1.125%, due 2023      
Stated interest rate 1.125%    
Unsecured debt $ 622   668
Senior Unsecured Notes 0.600% due 2023      
Stated interest rate 0.60%    
Unsecured debt $ 598   597
Senior Unsecured Notes 3.375% due 2024      
Stated interest rate 3.375%    
Unsecured debt $ 593   590
Senior Unsecured Notes 0.250% due 2024      
Stated interest rate 0.25%    
Unsecured debt $ 958   1,030
Senior Unsecured Notes, 1.150% Due 2025      
Stated interest rate 1.15%    
Unsecured debt $ 645   644
Senior Unsecured Notes 3.375% due 2025      
Stated interest rate 3.375%    
Unsecured debt $ 748   747
Senior Unsecured Notes 3.50% due 2026      
Stated interest rate 3.50%    
Unsecured debt $ 994   992
Senior Unsecured Notes,2.125%, due 2027      
Stated interest rate 2.125%    
Unsecured debt $ 845   909
Senior Unsecured Notes 3.650% due 2028      
Stated interest rate 3.65%    
Unsecured debt $ 597   596
Senior Unsecured Notes 0.750% due 2029      
Stated interest rate 0.75%    
Unsecured debt $ 901   969
Senior Unsecured Notes, 1.950% Due 2030      
Stated interest rate 1.95%    
Unsecured debt $ 990   989
Senior Unsecured Notes, 2.625% due 2030      
Stated interest rate 2.625%    
Unsecured debt $ 727   782
Senior Unsecured Notes 1.000% due 2031      
Stated interest rate 1.00%    
Unsecured debt $ 840   903
Senior Unsecured Notes 4.10% due 2043      
Stated interest rate 4.10%    
Unsecured debt $ 392   392
Senior Unsecured Notes 4.375% due 2044      
Stated interest rate 4.375%    
Unsecured debt $ 395   395
Senior Unsecured Notes 4.625% due 2046      
Stated interest rate 4.625%    
Unsecured debt $ 982   981
Senior Unsecured Notes, 2.900% due 2050      
Stated interest rate 2.90%    
Unsecured debt $ 642   641
Term Loan      
Long-term debt $ 0   $ 400
v3.22.0.1
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Contingency [Line Items]      
Effective income tax, percent 12.60% 18.20% 18.70%
Interest expense and penalties included in other income (expense), net $ (23) $ (35) $ (9)
Net operating loss carryforward recognized 283 41 $ 50
Accrued interest and penalties 150 133  
Operating loss carryforwards 602    
Operating loss carryforwards, subject to full valuation allowance 192    
Unrecognized tax benefits, interest on income tax expense 445 $ 456  
Wright      
Income Tax Contingency [Line Items]      
Operating loss carryforwards 183    
Operating loss carryforwards, subject to full valuation allowance 106    
United States      
Income Tax Contingency [Line Items]      
Operating loss carryforwards 403    
Foreign Tax Authority      
Income Tax Contingency [Line Items]      
Operating loss carryforwards 198    
Tax credit carryforward, amount 104    
Tax credit carryforward, valuation allowance $ 83    
v3.22.0.1
Income Taxes (Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations) (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
United States federal statutory rate 21.00% 21.00% 21.00%
United States state and local income taxes, less federal deduction 2.70% 0.10% 1.70%
Foreign income tax at rates other than 21% (6.90%) (3.30%) (4.60%)
Tax related to repatriation of foreign earnings 1.40% 3.00% (0.50%)
Intellectual property transfer (2.30%) (1.40%) 3.50%
Other (3.30%) (1.20%) (2.40%)
Effective income tax rate 12.60% 18.20% 18.70%
v3.22.0.1
Income Taxes (Schedule of Earnings before Income Taxes) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]                      
United States                 $ 433 $ 239 $ 366
International                 1,848 1,715 2,196
Earnings before income taxes $ 757 $ 495 $ 662 $ 367 $ 671 $ 780 $ (87) $ 590 $ 2,281 $ 1,954 $ 2,562
v3.22.0.1
Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Current income tax expense:      
United States federal $ 155 $ 80 $ (17)
United States state and local 97 20 46
International 272 207 324
Total current income tax expense 524 307 353
Deferred income tax (benefit) expense:      
United States federal (82) 1 10
United States state and local (23) (25) (1)
International (132) 72 117
Total deferred income tax (benefit) expense (237) 48 126
Total income tax expense $ 287 $ 355 $ 479
v3.22.0.1
Income Taxes (Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Deferred income tax assets:    
Inventories $ 513 $ 434
Product-related liabilities 39 48
Other accrued expenses 501 512
Depreciation and amortization 1,194 1,269
State income taxes 128 108
Share-based compensation 63 56
Net operating loss and other credit carryforwards 232 470
Other 191 166
Total deferred income tax assets 2,861 3,063
Less valuation allowances (164) (203)
Net deferred income tax assets 2,697 2,860
Deferred income tax liabilities:    
Depreciation and amortization (891) (1,286)
Undistributed earnings (114) (161)
Total deferred income tax liabilities (1,005) (1,447)
Net deferred income tax assets 1,692 1,413
Noncurrent deferred income tax assets 1,760 1,530
Noncurrent liabilities—Other liabilities $ (68) $ (117)
v3.22.0.1
Income Taxes (Schedule of Unresolved Income Tax Positions) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Beginning uncertain tax positions $ 457 $ 472
Increases related to current year income tax positions 13 12
Increases related to prior year income tax positions 4 5
Settlements and resolutions of income tax audits (18) (41)
Statute of limitations expirations and other 0 (7)
Foreign currency translation (12)  
Foreign currency translation   16
Ending uncertain tax positions $ 444 $ 457
v3.22.0.1
Retirement Plans (Schedule of Defined Contribution Plan Disclosures) (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Retirement Benefits [Abstract]      
Plan expense $ 259 $ 235 $ 205
Expense funded with Stryker common stock 37 34 31
Stryker common stock held by plan, amount $ 582 $ 542 $ 470
Stryker common stock held by plan, shares 2.2 2.2 2.2
Stryker common stock held by plan, value as a percentage of total plan assets 10.00% 11.00% 12.00%
v3.22.0.1
Retirement Plans (Schedule of Funded Status and Components of the Amounts Recognized in the Consolidated Balance Sheets and in Accumulated Other Comprehensive Gain (Loss), Before the Effect of Income Taxes) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Components of Net Periodic Pension Cost      
Service cost $ (72) $ (63) $ (41)
Interest cost (7) (8) (12)
Expected return on plan assets 11 13 12
Amortization of prior service cost and transition amount 1 1 1
Recognized actuarial loss (16) (13) (9)
Curtailment gain 9    
Net periodic benefit cost (74) (70) (49)
Net actuarial gain (loss) 132 (117) (74)
Recognized net actuarial loss 16 13 9
Prior service cost and transition amount (1) (1) (1)
Curtailment gain (9) 0 0
Total recognized in OCI 138 (105) (66)
Total recognized in net periodic benefit cost and OCI $ 64 $ (175) $ (115)
Defined Benefit Plan, Assumptions Used in Calculations [Abstract]      
Discount rate 0.80% 1.00% 1.90%
Expected return on plan assets 2.50% 2.90% 3.50%
Expected return on plan assets 2.60% 2.90% 2.90%
Weighted-average discount rate used to determine projected benefit obligations 1.10% 0.80% 1.00%
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Fair value of plan assets $ 543 $ 522  
Benefit obligations (1,036) (1,118) $ (869)
Funded status (493) (596)  
Current liabilities—accrued compensation (2) (2)  
Noncurrent liabilities—other liabilities (491) (594)  
Unrecognized net actuarial loss (208) (346)  
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent      
Defined Benefit Plan, Information about Plan Assets [Abstract]      
Unrecognized prior service credit 7 8  
Unrecognized net actuarial loss $ (215) $ (354)  
v3.22.0.1
Retirement Plans (Schedule of Change in Benefit Obligations (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Beginning projected benefit obligations $ 1,118 $ 869  
Service cost 72 63 $ 41
Interest cost 7 8 12
Foreign exchange impact (70) 80  
Employee contributions 8 8  
Actuarial (gains) losses (71) 110  
Curtailment gain (23) 0  
Benefits paid (5) (20)  
Ending projected benefit obligations 1,036 1,118 $ 869
Ending accumulated benefit obligations $ 987 $ 1,056  
v3.22.0.1
Retirement Plans (Change in Plan Assets) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Beginning fair value of plan assets $ 522 $ 428
Actual return 17 30
Employer contributions 33 33
Employee contributions 8 8
Foreign exchange impact (29) 37
Benefits paid (8) (14)
Ending fair value of plan assets $ 543 $ 522
v3.22.0.1
Retirement Plans (Schedule of Target and Actual Allocation of Plan Assets) (Details)
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 100.00%  
Actual plan asset allocations 100.00% 100.00%
Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 23.00%  
Actual plan asset allocations 23.00% 23.00%
Debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 39.00%  
Actual plan asset allocations 41.00% 44.00%
Other    
Defined Benefit Plan Disclosure [Line Items]    
Target plan asset allocations 38.00%  
Actual plan asset allocations 36.00% 33.00%
v3.22.0.1
Retirement Plans (Schedule of Valuation of the Company's Pension Plan Assets by Pricing Categories) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 543 $ 522
(Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 55 46
(Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 389 372
(Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 99 104
Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 21 14
Cash and cash equivalents | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 21 14
Cash and cash equivalents | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Cash and cash equivalents | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 147 131
Equity securities | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 28 23
Equity securities | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 119 108
Equity securities | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Corporate debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 204 203
Corporate debt securities | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 2 2
Corporate debt securities | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 202 201
Corporate debt securities | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0 0
Other    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 171 174
Other | (Level 1)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 4 7
Other | (Level 2)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 68 63
Other | (Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 99 $ 104
v3.22.0.1
Retirement Plans (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]    
Actual return $ 17 $ 30
(Level 3)    
Defined Benefit Plan Disclosure [Line Items]    
Actual return (5)  
Estimated future employer contributions in next fiscal year $ 21  
v3.22.0.1
Retirement Plans (Expected Benefit Payments) (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Retirement Benefits [Abstract]  
2022 $ 21
2023 21
2024 27
2025 22
2026 23
2027-2031 $ 138
v3.22.0.1
Summary of Quarterly Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Quarterly Financial Data [Abstract]                      
Net sales $ 4,701,000 $ 4,160,000 $ 4,294,000 $ 3,953,000 $ 4,262,000 $ 3,737,000 $ 2,764,000 $ 3,588,000 $ 17,108,000 $ 14,351,000 $ 14,884,000
Gross profit 3,045,000 2,642,000 2,772,000 2,509,000 2,717,000 2,461,000 1,548,000 2,331,000 10,968,000 9,057,000 9,696,000
Earnings (loss) before income taxes 757,000 495,000 662,000 367,000 671,000 780,000 (87,000) 590,000 2,281,000 1,954,000 2,562,000
Net earnings (loss) $ 662,000 $ 438,000 $ 592,000 $ 302,000 $ 568,000 $ 621,000 $ (83,000) $ 493,000 $ 1,994,000 $ 1,599,000 $ 2,083,000
Basic net earnings per share of common stock (in dollars per share) $ 1.75 $ 1.17 $ 1.57 $ 0.80 $ 1.51 $ 1.66 $ (0.22) $ 1.32 $ 5.29 $ 4.26 $ 5.57
Diluted net earnings per share of common stock (in dollars per share) 1.73 1.14 1.55 0.79 1.49 1.63 (0.22) 1.30 $ 5.21 $ 4.20 $ 5.48
Dividends declared per share of common stock (in dollars per share) $ 0.695 $ 0.630 $ 0.630 $ 0.630 $ 0.630 $ 0.575 $ 0.575 $ 0.575      
v3.22.0.1
Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting [Abstract]                      
Number of reportable segments | segment                 2    
Segment Reporting Information [Line Items]                      
Number of reportable segments | segment                 2    
Net sales $ 4,701,000 $ 4,160,000 $ 4,294,000 $ 3,953,000 $ 4,262,000 $ 3,737,000 $ 2,764,000 $ 3,588,000 $ 17,108,000 $ 14,351,000 $ 14,884,000
Depreciation and amortization                 1,272,000 1,076,000 1,044,000
Segment net earnings (loss)                 2,584,000 2,223,000 2,713,000
Amortization of intangible assets                 (619,000) (472,000) (464,000)
Net earnings (loss) $ 662,000 $ 438,000 $ 592,000 $ 302,000 $ 568,000 $ 621,000 $ (83,000) $ 493,000 1,994,000 1,599,000 2,083,000
MedSurg and Neurotechnology                      
Segment Reporting Information [Line Items]                      
Net sales                 9,538,000 8,345,000 8,475,000
Orthopaedics and Spine                      
Segment Reporting Information [Line Items]                      
Net sales                 7,570,000 6,006,000 6,409,000
Operating Segments                      
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 1,147,000 954,000 945,000
Segment operating income                 4,987,000 4,002,000 4,388,000
Operating Segments | MedSurg and Neurotechnology                      
Segment Reporting Information [Line Items]                      
Net sales                 9,538,000 8,345,000 8,475,000
Depreciation and amortization                 518,000 496,000 488,000
Segment net earnings (loss)                 2,807,000 2,414,000 2,304,000
Operating Segments | Orthopaedics and Spine                      
Segment Reporting Information [Line Items]                      
Net sales                 7,570,000 6,006,000 6,409,000
Depreciation and amortization                 629,000 458,000 457,000
Segment net earnings (loss)                 2,180,000 1,588,000 2,084,000
Corporate                      
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 125,000 122,000 99,000
Segment Reconciling Items                      
Segment Reporting Information [Line Items]                      
Segment operating income                 (605,000) (503,000) (480,000)
Acquisition and integration-related charges                 (585,000) (242,000) (275,000)
Amortization of intangible assets                 (619,000) (472,000) (464,000)
Restructuring-related and other charges                 (386,000) (458,000) (226,000)
Medical device regulations                 (107,000) (81,000) (62,000)
Recall-related matters                 (103,000) (17,000) (192,000)
Regulatory and legal matters                 2,000 (6,000) 24,000
Net earnings (loss)                 $ 2,584,000 $ 2,223,000 $ 2,713,000
v3.22.0.1
Segment and Geographic Data (Segment Information) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Assets $ 34,631 $ 34,330 $ 30,167
Capital Expenditures During Period 525 487 649
Operating Segments      
Segment Reporting Information [Line Items]      
Assets 33,367 33,340 28,797
Capital Expenditures During Period 362 342 419
Operating Segments | MedSurg and Neurotechnology      
Segment Reporting Information [Line Items]      
Assets 15,218 15,250 16,270
Capital Expenditures During Period 197 192 281
Operating Segments | Orthopaedics and Spine      
Segment Reporting Information [Line Items]      
Assets 18,149 18,090 12,527
Capital Expenditures During Period 165 150 138
Corporate      
Segment Reporting Information [Line Items]      
Assets 1,264 990 1,370
Capital Expenditures During Period $ 163 $ 145 $ 230
v3.22.0.1
Segment and Geographic Data (Geographic Information on Net Sales and Long-Lived Assets) (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]                      
Net sales $ 4,701,000 $ 4,160,000 $ 4,294,000 $ 3,953,000 $ 4,262,000 $ 3,737,000 $ 2,764,000 $ 3,588,000 $ 17,108,000 $ 14,351,000 $ 14,884,000
Net Property, Plant & Equipment 2,833,000       2,752,000       2,833,000 2,752,000  
United States                      
Segment Reporting Information [Line Items]                      
Net sales                 12,321,000 10,455,000 10,957,000
Net Property, Plant & Equipment 1,717,000       1,645,000       1,717,000 1,645,000  
Europe, Middle East, Africa                      
Segment Reporting Information [Line Items]                      
Net sales                 2,299,000 1,818,000 1,888,000
Net Property, Plant & Equipment 941,000       938,000       941,000 938,000  
Asia Pacific                      
Segment Reporting Information [Line Items]                      
Net sales                 1,973,000 1,630,000 1,617,000
Net Property, Plant & Equipment 76,000       91,000       76,000 91,000  
Other foreign countries                      
Segment Reporting Information [Line Items]                      
Net sales                 515,000 448,000 $ 422,000
Net Property, Plant & Equipment $ 99,000       $ 78,000       $ 99,000 $ 78,000  
v3.22.0.1
Asset Impairments (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]        
Asset impairments   $ 264 $ 215 $ 16
Long-Lived Assets and Intangible Assets        
Property, Plant and Equipment [Line Items]        
Asset impairments $ 105      
In-Process R&D, Other Intangible Assets and Property, Plant and Equipment        
Property, Plant and Equipment [Line Items]        
Asset impairments   $ 159    
Global ERP System        
Property, Plant and Equipment [Line Items]        
Asset impairments     $ 195  
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | CHINA        
Property, Plant and Equipment [Line Items]        
Concentration risk (as a percent)   2.50%    
v3.22.0.1
Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Allowance, Notes Receivable - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Balance at Beginning of Period $ 131 $ 88 $ 64
Charged to Costs & Expenses 61 65 39
Uncollectible Amounts Written Off, Net of Recoveries 23 22 13
Effect of Changes in Foreign Currency Exchange Rates 2 0 2
Balance at End of Period $ 167 $ 131 $ 88